<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00422</drugbank-id>
  <drugbank-id>APRD00657</drugbank-id>
  <name>Methylphenidate</name>
  <description>Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate, [DB01576], and [DB01255] are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.  &#13;
&#13;
While its exact mechanism is unclear, methylphenidate (MPH) has been shown to act as a norepinephrine and dopamine reuptake inhibitor (NDRI), thereby increasing the presence of these neurotransmitters in the extraneuronal space and prolonging their action.[A177541] There is a dose-related effect of psychostimulants on receptor stimulation, where higher doses are shown to increase norepinephrine (NE) and dopamine (DA) efflux throughout the brain which can result in impaired cognition and locomotor-activating effects. In contrast, low doses are found to selectively activate NE and DA neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology, thereby improving clinical efficacy and preventing side effects.[A177547] The lower doses used to treat ADHD are not associated with the locomotor-activating effects associated with higher doses and instead reduce movement, impulsivity, and increase cognitive function including sustained attention and working memory.[A177541, A177544] Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha-1 adrenergic receptor activity.[A177550] Clinical findings have shown that children with ADHD have an abnormality in the dopamine transporter gene (DAT1), the D4 receptor gene (DRD-4), and/or the D2 receptor gene that may be at least partly overcome by the dopaminergic effects of methylphenidate, suggesting a possible mode of action.[F4474]&#13;
&#13;
When provided as Biphentin®, methylphenidate is released through a multi-layer release delivery system (MLRTM) where 40% of the dose is provided as an immediate release and 60% is provided through a gradual release. Biphentin was designed to be an alternative to separate doses of immediate-release (IR) methylphenidate by providing a biphasic concentration-time profile when given as a single dose. The MLRTM release system allows for a sustained effect for 10-12 hours, allowing for once-daily dosing that covers the major times that ADHD impairment might occur (such as school, homework periods, during the work day, etc).&#13;
&#13;
When provided as Concerta®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is provided through a gradual release.[A631] OROS is comprised of an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. Within an aqueous environment, such as the stomach, the drug overcoat, which consists of 22% of the dose, dissolves within one hour, providing an initial immediate-release formulation of methylphenidate. Water then permeates through the membrane into the tablet core where the osmotically active polymer excipients expand, allowing methylphenidate to release slowly through the orifice over a period of 6-7 hours. Concerta also provides a sustained 10-12 hour effect, allowing for once-daily dosing.&#13;
&#13;
Methylphenidate contains a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. This abuse potential is likely related to the effects associated with higher doses of methylphenidate, which induce surface expression of the dopamine transporter (DAT).[A177553] In particular, increased dopamine in key brain areas is associated with the reinforcing and addictive properties of psychostimulants such as methylphenidate, and even amplifies the potency and reinforcing effects of other drugs of abuse such as amphetamines, making ADHD sufferers more susceptible to their addictive effects.[A177556] Concerns about abuse potential have spurred research into medications with fewer effects on DAT and the use of non-stimulant ADHD medications including [DB00289] and [DB01018].</description>
  <cas-number>113-45-1</cas-number>
  <unii>207ZZ9QZ49</unii>
  <average-mass>233.3062</average-mass>
  <monoisotopic-mass>233.141578857</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A631</ref-id>
        <pubmed-id>11524026</pubmed-id>
        <citation>Keating GM, McClellan K, Jarvis B: Methylphenidate (OROS formulation). CNS Drugs. 2001;15(6):495-500; discussion 501-3.</citation>
      </article>
      <article>
        <ref-id>A632</ref-id>
        <pubmed-id>17201613</pubmed-id>
        <citation>Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98.</citation>
      </article>
      <article>
        <ref-id>A633</ref-id>
        <pubmed-id>15661631</pubmed-id>
        <citation>Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93.</citation>
      </article>
      <article>
        <ref-id>A634</ref-id>
        <pubmed-id>2190251</pubmed-id>
        <citation>Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM: Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990 Apr;32(1):9-17.</citation>
      </article>
      <article>
        <ref-id>A176026</ref-id>
        <pubmed-id>22763750</pubmed-id>
        <citation>Hodgkins P, Shaw M, Coghill D, Hechtman L: Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012 Sep;21(9):477-92. doi: 10.1007/s00787-012-0286-5. Epub 2012 Jul 5.</citation>
      </article>
      <article>
        <ref-id>A177541</ref-id>
        <pubmed-id>16806100</pubmed-id>
        <citation>Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC: Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006 Nov 15;60(10):1111-20. doi: 10.1016/j.biopsych.2006.04.022. Epub 2006 Jun 23.</citation>
      </article>
      <article>
        <ref-id>A177544</ref-id>
        <pubmed-id>9708845</pubmed-id>
        <citation>Solanto MV: Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998 Jul;94(1):127-52.</citation>
      </article>
      <article>
        <ref-id>A177547</ref-id>
        <pubmed-id>18591484</pubmed-id>
        <citation>Brennan AR, Arnsten AF: Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci. 2008;1129:236-45. doi: 10.1196/annals.1417.007.</citation>
      </article>
      <article>
        <ref-id>A177550</ref-id>
        <pubmed-id>21890109</pubmed-id>
        <citation>Berridge CW, Shumsky JS, Andrzejewski ME, McGaughy JA, Spencer RC, Devilbiss DM, Waterhouse BD: Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic alpha(1) - and alpha(2)-receptors. Biol Psychiatry. 2012 Mar 1;71(5):467-73. doi: 10.1016/j.biopsych.2011.07.022. Epub 2011 Sep 3.</citation>
      </article>
      <article>
        <ref-id>A177553</ref-id>
        <pubmed-id>24193139</pubmed-id>
        <citation>Calipari ES, Ferris MJ, Salahpour A, Caron MG, Jones SR: Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun. 2013;4:2720. doi: 10.1038/ncomms3720.</citation>
      </article>
      <article>
        <ref-id>A177556</ref-id>
        <pubmed-id>30633928</pubmed-id>
        <citation>Marshall CA, Brodnik ZD, Mortensen OV, Reith MEA, Shumsky JS, Waterhouse BD, Espana RA, Kortagere S: Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention. Neuropharmacology. 2019 Apr;148:178-188. doi: 10.1016/j.neuropharm.2019.01.003. Epub 2019 Jan 8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L6037</ref-id>
        <title>CADDRA - Canadian ADHD Practice Guidelines</title>
        <url>https://www.caddra.ca/pdfs/caddraGuidelines2011.pdf</url>
      </link>
      <link>
        <ref-id>L10073</ref-id>
        <title>Concerta FDA label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf</url>
      </link>
      <link>
        <ref-id>L10442</ref-id>
        <title>FDA Approved Drug Products: Daytrana® transdermal system</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021514s030lbl.pdf</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F4474</ref-id>
        <title>Health Canada Label - Concerta</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/474/original/Health_Canada_-_Concerta.PDF?1556049353</url>
      </attachment>
      <attachment>
        <ref-id>F4480</ref-id>
        <title>Health Canada Label - Biphentin</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/480/original/Health_Canada_-_Biphentin.PDF?1556049613</url>
      </attachment>
      <attachment>
        <ref-id>F4483</ref-id>
        <title>Health Canada - Ritalin</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/483/original/Health_Canada_-_Ritalin.PDF?1556050208</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.</indication>
  <pharmacodynamics>Methylphenidate is a racemic mixture comprised of the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer. Radioligand binding studies demonstrate that binding of methylphenidate in the brain is localized to dopamine-rich areas, in particular in the prefrontal cortex which has been demonstrated to play a prominent role in ADHD pathophysiology.[A177547] In a number of animal models, methylphenidate enhances locomotor activity and induces stereotypic behaviours. </pharmacodynamics>
  <mechanism-of-action>While its exact mechanism is unclear, methylphenidate (MPH) has been shown to act as a norepinephrine and dopamine reuptake inhibitor (NDRI), thereby increasing the presence of these neurotransmitters in the extraneuronal space and prolonging their action.[A177541] There is a dose-related effect of psychostimulants on receptor stimulation, where higher doses are shown to increase norepinephrine (NE) and dopamine (DA) efflux throughout the brain which can result in impaired cognition and locomotor-activating effects. In contrast, low doses are found to selectively activate NE and DE neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology, thereby improving clinical efficacy and preventing side effects.[A177547] The lower doses used to treat ADHD are not associated with the locomotor-activating effects associated with higher doses and instead reduce movement, impulsivity, and increase cognitive function including sustained attention and working memory.[A177541, A177544] Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha-1 adrenergic receptor activity.[A177550].&#13;
&#13;
Clinical findings have shown that children with ADHD have an abnormality in the dopamine transporter gene (DAT1), the D4 receptor gene (DRD-4), and/or the D2 receptor gene that may be at least partly overcome by the dopaminergic effects of methylphenidate, suggesting a possible mode of action.[F4474]</mechanism-of-action>
  <toxicity>Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD&lt;sub&gt;50&lt;/sub&gt;=190mg/kg (orally in mice)</toxicity>
  <metabolism>Methylphenidate is hepatically metabolized. More specifically, it is rapidly and extensively metabolized by carboxylesterase CES1A1. Via this enzyme, methylphenidate undergoes de-esterification to ritalinic acid (a-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.</metabolism>
  <absorption>Concerta®: Methylphenidate is readily absorbed. Following oral administration of Concerta, plasma methylhphenidate concentrations reach an initial maximum at about 1 hour followed by gradual ascending concentrations over the next 5-9 hours. Mean times to reach peak plasma concentrations across all doses of Concerta occurred between 6-10 hours. Once daily dosing minimizes the fluctuations between peak and trough concentrations associated with multiple doses of immediate-release methylphenidate treatments.[F4474] Depending on the doses provided, Cmax was found to range from 6.0-15.0ng/mL, Tmax ranged from 8.1-9.4h, and AUC ranged from 50.4-121.5 ng·h/mL in children.[F4474]&#13;
&#13;
When provided as Concerta®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is provided through a gradual release.[A631] OROS is comprised of an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. Within an aqueous environment, such as the stomach, the drug overcoat, which consists of 22% of the dose, dissolves within one hour, providing an initial immediate-release formulation of methylphenidate. Water then permeates through the membrane into the tablet core where the osmotically active polymer excipients expand, allowing methylphenidate to release slowly through the orifice over a period of 6-7 hours. Concerta also provides a sustained 10-12 hour effect, allowing for once-daily dosing.&#13;
&#13;
Biphentin®: Methylphenidate is rapidly and extensively absorbed following oral administration, with peak blood levels obtained in 1-3 hours.[F4480]&#13;
&#13;
When provided as Biphentin®, methylphenidate is released through a multi-layer release delivery system (MLRTM) where 40% of the dose is provided as an immediate release and 60% is provided through a gradual release. Biphentin was designed to be an alternative to separate doses of immediate-release (IR) methylphenidate by providing a biphasic concentration-time profile when given as a single dose. The MLRTM release system allows for a sustained effect for 10-12 hours, allowing for once-daily dosing that covers the major times that ADHD impairment might occur (such as school, homework periods, during the workday, etc).&#13;
&#13;
Methylphenidate (immediate release): Methylphenidate hydrochloride is rapidly and extensively absorbed from the tablets following oral administration; however, owing to extensive first-pass metabolism, bioavailability is low (approx. 30%) and large individual differences exist (11-52%). In one study, the administration of methylphenidate hydrochloride with food accelerated absorption but had no effect on the amount absorbed. Peak plasma concentrations of 10.8 and 7.8 ng/mL were observed, on average, 2 hours after administration of 0.30 mg/kg in children and adults, respectively. Peak plasma concentrations showed marked variability between subjects. Both the area under the concentration-time curve (AUC), and the peak plasma concentrations (Cmax) showed dose-proportionality.[F4483]</absorption>
  <half-life>Concerta: The half-life of methylphenidate in adults following oral administration of Concerta® was approximately 3.5 h.[F4474]&#13;
&#13;
Biphentin: Methylphenidate is eliminated from plasma with a mean half-life of 2.4 hours in children and 2.1 hours in adults.[F4480]&#13;
&#13;
Methylphenidate (immediate release): Methylphenidate is eliminated from the plasma with a mean half-life of 2.4 hours in children and 2.1 hours in adults.[F4483]&#13;
</half-life>
  <protein-binding>Concerta: In humans, 15 ± 5% of methylphenidate in the blood is bound to plasma proteins. [F4474]&#13;
&#13;
Biphentin: In blood, methylphenidate and its metabolites are distributed between plasma (57%) and&#13;
erythrocytes (43%). Methylphenidate and its metabolites exhibit low plasma protein binding&#13;
(approximately 15%).[F4480]&#13;
&#13;
Methylphenidate (immediate release): In blood, methylphenidate and its metabolites are distributed between plasma (57%) and erythrocytes (43%). Methylphenidate and its metabolites exhibit low plasma protein binding (approx. 15%).[F4483]</protein-binding>
  <route-of-elimination>After oral administration of an immediate release formulation of methylphenidate, 78%-97% of the dose is excreted in the urine and 1%-3% in the feces in the form of metabolites within 48-96 hours. Only small quantities (&lt;1%) of unchanged methylphenidate appear in the urine. Most of the dose is excreted in the urine as ritalinic acid (60%-86%), the remainder being accounted for by minor metabolites.</route-of-elimination>
  <volume-of-distribution>Concerta: Plasma methylphenidate concentrations in adults decline bi-exponentially&#13;
following oral administration.[F4474]&#13;
&#13;
Biphentin: The apparent distribution volume of methylphenidate in children is approximately 20 L/kg, with&#13;
substantial variability (11 to 33 L/kg).[F4480]&#13;
&#13;
Methylphenidate (immediate release): The apparent distribution volume of methylphenidate in children was approximately 20 L/kg, with substantial variability (11-33 L/kg). The volume of distribution after an intravenous dose (Vss) is 2.23 L/kg for the racemate in healthy adult volunteers.[F4483]</volume-of-distribution>
  <clearance>The apparent mean systemic clearance after an oral dose is 10.2 and 10.5 L/h/kg in children and adults, respectively for a 0.3 mg/kg dose, and 0.565 L/h/kg after an intravenous dose of the racemate in healthy adult volunteers.[F4483]&#13;
</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.</description>
    <direct-parent>Aralkylamines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic nitrogen compounds</superclass>
    <class>Organonitrogen compounds</class>
    <subclass>Amines</subclass>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Dialkylamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Methyl esters</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Piperidines</alternative-parent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methyl ester</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Secondary aliphatic amine</substituent>
    <substituent>Secondary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000117</drugbank-id>
      <name>Methylphenidate hydrochloride</name>
      <unii>4B3SC438HI</unii>
      <cas-number>23655-65-4</cas-number>
      <inchikey>JUMYIBMBTDDLNG-UHFFFAOYSA-N</inchikey>
      <average-mass>269.767</average-mass>
      <monoisotopic-mass>269.118256596</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Methyl phenidylacetate</synonym>
    <synonym language="english" coder="iupac">methyl phenyl(piperidin-2-yl)acetate</synonym>
    <synonym language="english" coder="">methyl α-phenyl-α-(2-piperidyl)acetate</synonym>
    <synonym language="english" coder="">methyl α-phenyl-α-2-piperidinylacetate</synonym>
    <synonym language="english" coder="">Methylphenidan</synonym>
    <synonym language="english" coder="inn/usan">Methylphenidate</synonym>
    <synonym language="latin" coder="inn">Methylphenidatum</synonym>
    <synonym language="italian" coder="inn">Metilfenidato</synonym>
    <synonym language="english" coder="">MPH</synonym>
    <synonym language="english" coder="">α-phenyl-2-piperidineacetic acid methyl ester</synonym>
  </synonyms>
  <products>
    <product>
      <name>Act Methylphenidate ER</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441934</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Methylphenidate ER</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441942</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Methylphenidate ER</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441950</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Methylphenidate ER</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441969</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Adhansia XR</name>
      <labeller>Adlon Therapeutics L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>72912-525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212038</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adhansia XR</name>
      <labeller>Adlon Therapeutics L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>72912-535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212038</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adhansia XR</name>
      <labeller>Adlon Therapeutics L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>72912-545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>45 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212038</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adhansia XR</name>
      <labeller>Adlon Therapeutics L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>72912-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>55 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212038</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adhansia XR</name>
      <labeller>Adlon Therapeutics L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>72912-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212038</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adhansia XR</name>
      <labeller>Adlon Therapeutics L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>72912-585</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>85 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212038</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apo-methylphenidate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249324</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249332</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273950</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate ER</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02330377</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate ER</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02452731</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate ER</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02452758</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate ER</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02452766</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-methylphenidate SR</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02266687</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aptensio XR</name>
      <labeller>Rhodes Pharmaceuticals L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>42858-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484900</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484919</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484927</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484935</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484943</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484951</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484978</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bar-methylphenidate HCl CR</name>
      <labeller>Bard Pharmaceuticals (1990) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02484986</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277131</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277158</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277166</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277174</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277182</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277190</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277204</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biphentin</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277212</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Caremark L.L.C.</labeller>
      <ndc-id/>
      <ndc-product-code>0339-4170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-04</started-marketing-on>
      <ended-marketing-on>2011-08-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Caremark L.L.C.</labeller>
      <ndc-id/>
      <ndc-product-code>0339-4169</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-23</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4957</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4759</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4789</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Alza</labeller>
      <ndc-id/>
      <ndc-product-code>17314-5850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on>2012-04-10</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Alza</labeller>
      <ndc-id/>
      <ndc-product-code>17314-5853</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on>2012-04-10</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Alza</labeller>
      <ndc-id/>
      <ndc-product-code>17314-5851</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on>2012-04-10</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Alza</labeller>
      <ndc-id/>
      <ndc-product-code>17314-5852</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on>2012-04-10</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-585</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-588</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-586</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-587</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247732</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247733</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Concerta</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250241</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cotempla XR-ODT</name>
      <labeller>Neos Therapeutics, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>70165-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>8.6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205489</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cotempla XR-ODT</name>
      <labeller>Neos Therapeutics, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>70165-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>17.3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205489</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cotempla XR-ODT</name>
      <labeller>Neos Therapeutics, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>70165-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>25.9 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205489</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Shire</labeller>
      <ndc-id/>
      <ndc-product-code>54092-552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on>2012-04-02</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>10 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Shire</labeller>
      <ndc-id/>
      <ndc-product-code>54092-553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on>2012-11-27</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>15 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Shire</labeller>
      <ndc-id/>
      <ndc-product-code>54092-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on>2012-10-12</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>20 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Shire</labeller>
      <ndc-id/>
      <ndc-product-code>54092-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on>2012-12-15</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>30 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Noven Therapeutics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68968-5552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>10 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Noven Therapeutics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68968-5553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>15 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Noven Therapeutics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68968-5554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>20 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daytrana</name>
      <labeller>Noven Therapeutics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68968-5555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>30 mg/9h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA021514</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470292</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470306</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470314</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470322</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470330</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470349</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Foquest</name>
      <labeller>Purdue Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470357</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>JORNAY PM Extended-Release</name>
      <labeller>Ironshore Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71376-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209311</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>JORNAY PM Extended-Release</name>
      <labeller>Ironshore Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71376-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209311</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>JORNAY PM Extended-Release</name>
      <labeller>Ironshore Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71376-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209311</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>JORNAY PM Extended-Release</name>
      <labeller>Ironshore Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71376-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>80 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209311</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>JORNAY PM Extended-Release</name>
      <labeller>Ironshore Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71376-205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209311</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate</name>
      <labeller>UCB Pharma, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>53014-593</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-04</started-marketing-on>
      <ended-marketing-on>2006-08-14</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5397</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0668</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6234</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-581</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-583</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>McKesson Corporation dba RX Pak</labeller>
      <ndc-id/>
      <ndc-product-code>65084-466</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on>2016-06-30</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>McKesson Corporation dba RX Pak</labeller>
      <ndc-id/>
      <ndc-product-code>65084-467</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-12</started-marketing-on>
      <ended-marketing-on>2016-06-30</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>McKesson Corporation dba RX Pak</labeller>
      <ndc-id/>
      <ndc-product-code>65084-468</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-18</started-marketing-on>
      <ended-marketing-on>2019-09-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate CD</name>
      <labeller>McKesson Corporation dba RX Pak</labeller>
      <ndc-id/>
      <ndc-product-code>65084-469</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate ER</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate ER</name>
      <labeller>Upstate Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65580-594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Metadate ER</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-2562</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA089601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-04</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-537</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-760</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on>2014-01-01</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-761</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on>2014-01-01</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Shionogi</labeller>
      <ndc-id/>
      <ndc-product-code>59630-762</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on>2014-01-01</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Mallinckrodt Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2006-07-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Mallinckrodt Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2006-07-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Mallinckrodt Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2006-07-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Alliant Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68188-881</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-21</started-marketing-on>
      <ended-marketing-on>2006-06-21</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Alliant Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68188-882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-21</started-marketing-on>
      <ended-marketing-on>2006-06-21</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Alliant Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68188-132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-28</started-marketing-on>
      <ended-marketing-on>2007-06-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Alliant Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68188-135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-28</started-marketing-on>
      <ended-marketing-on>2007-06-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>Alliant Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68188-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-28</started-marketing-on>
      <ended-marketing-on>2007-06-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>SHIONOGI INC.</labeller>
      <ndc-id/>
      <ndc-product-code>59630-750</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021419</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin</name>
      <labeller>SHIONOGI INC.</labeller>
      <ndc-id/>
      <ndc-product-code>59630-755</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021419</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin ER</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on>2013-03-31</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin ER</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin ER</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2015-06-30</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin ER</name>
      <labeller>Mallinckrodt Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1423</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2006-07-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylin ER</name>
      <labeller>Mallinckrodt Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-07</started-marketing-on>
      <ended-marketing-on>2006-07-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1704</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2974</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0733</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-163</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-164</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207485</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2362</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2363</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2364</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2361</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326221</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-12</started-marketing-on>
      <ended-marketing-on>2019-04-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326248</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-12</started-marketing-on>
      <ended-marketing-on>2019-04-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Methylphenidate</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326256</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-12</started-marketing-on>
      <ended-marketing-on>2019-04-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Methylphenidate HCl Oral Solution</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-3005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021419</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate HCl Oral Solution</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-3010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021419</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086428</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6262</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2018-10-16</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2018-10-16</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2018-10-16</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086429</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085799</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Unither Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>53014-532</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086428</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204602</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-931</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204602</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-06</started-marketing-on>
      <ended-marketing-on>2018-06-07</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on>2016-04-26</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-573</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-574</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-575</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70408-369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-06</started-marketing-on>
      <ended-marketing-on>2018-04-18</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201466</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70408-368</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-06</started-marketing-on>
      <ended-marketing-on>2018-04-18</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201466</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-04</started-marketing-on>
      <ended-marketing-on>2018-06-08</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-2715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-04</started-marketing-on>
      <ended-marketing-on>2018-06-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29033-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-03</started-marketing-on>
      <ended-marketing-on>2017-03-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29033-209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-03</started-marketing-on>
      <ended-marketing-on>2017-03-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29033-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-03</started-marketing-on>
      <ended-marketing-on>2017-03-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-01</started-marketing-on>
      <ended-marketing-on>2017-02-27</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-602</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-01</started-marketing-on>
      <ended-marketing-on>2017-02-27</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-01</started-marketing-on>
      <ended-marketing-on>2017-02-27</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-01</started-marketing-on>
      <ended-marketing-on>2017-02-27</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Upstate Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65580-531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086429</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Upstate Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65580-530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085799</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Upstate Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65580-532</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086428</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on>2017-04-28</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201466</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Caraco Pharmaceutical Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-368</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on>2017-04-28</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201466</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>45963-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-26</started-marketing-on>
      <ended-marketing-on>2017-09-28</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>45963-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-28</started-marketing-on>
      <ended-marketing-on>2017-08-28</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>45963-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-28</started-marketing-on>
      <ended-marketing-on>2017-09-28</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis South Atlantic LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67767-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on>2017-04-30</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis South Atlantic LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67767-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis South Atlantic LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67767-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-01</started-marketing-on>
      <ended-marketing-on>2017-11-30</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>County Line Pharamceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>43199-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>County Line Pharamceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>43199-042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29033-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-26</started-marketing-on>
      <ended-marketing-on>2017-02-07</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204954</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29033-205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-26</started-marketing-on>
      <ended-marketing-on>2017-02-07</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204954</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Nostrum Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>29033-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-26</started-marketing-on>
      <ended-marketing-on>2017-02-07</ended-marketing-on>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204954</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-844</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1144</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1445</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1473</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-952</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on>2018-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-953</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on>2018-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-954</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on>2018-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207587</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1566</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-30</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1567</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-30</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1568</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-30</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-30</started-marketing-on>
      <ended-marketing-on>2018-10-23</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-568</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-14</started-marketing-on>
      <ended-marketing-on>2018-10-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-14</started-marketing-on>
      <ended-marketing-on>2018-10-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-537</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on>2018-10-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>UCB Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0781-8840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>UCB Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0781-8841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>UCB Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0781-8842</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>UCB Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0781-8843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate hydrochloride</name>
      <labeller>Watson Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-11</started-marketing-on>
      <ended-marketing-on>2006-05-11</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-2531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086429</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-2530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA085799</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-2532</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA086428</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091159</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091159</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091159</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on>2019-12-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on>2019-10-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on>2019-12-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on>2019-11-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on>2019-12-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>CorePharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>64720-406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on>2019-11-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-926</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-927</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-928</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201466</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201466</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205756</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-222</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205756</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-223</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205756</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210818</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210818</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-417</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210818</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210818</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206726</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8156</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206726</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206726</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8158</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206726</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-229</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57664-230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate Hydrochloride</name>
      <labeller>Patriot Pharmaceuticals, LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>10147-0685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate Hydrochloride</name>
      <labeller>Patriot Pharmaceuticals, LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>10147-0688</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate Hydrochloride</name>
      <labeller>Patriot Pharmaceuticals, LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>10147-0686</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate Hydrochloride</name>
      <labeller>Patriot Pharmaceuticals, LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>10147-0687</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62037-725</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62037-734</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62037-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62037-727</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076655</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>ANI Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62559-790</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>ANI Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62559-791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Eywa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71930-024</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210139</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Eywa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71930-025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210139</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-823</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-31</started-marketing-on>
      <ended-marketing-on>2018-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040300</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on>2021-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2716</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on>2021-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2717</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on>2021-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2718</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-01</started-marketing-on>
      <ended-marketing-on>2021-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-821</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-823</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceutical Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-173</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceutical Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-174</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceutical Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-5882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-01-01</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-5883</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-01-01</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-5884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-01-01</started-marketing-on>
      <ended-marketing-on>2020-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Neolpharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55466-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208737</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Neolpharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55466-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208737</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Neolpharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55466-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208737</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204115</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204115</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204115</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-1219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207416</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1736</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1737</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1739</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1740</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1741</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1800</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091159</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091159</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091159</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Tris Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>27808-058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Tris Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>27808-059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091601</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-541</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-629</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62175-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62175-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62175-312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62175-313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209276</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-381</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209276</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Aurolife Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13107-382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209276</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-952</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-953</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-954</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Camber Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>31722-955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5748</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on>2022-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5749</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on>2022-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5753</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on>2021-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-829</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-21</started-marketing-on>
      <ended-marketing-on>2020-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-833</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-21</started-marketing-on>
      <ended-marketing-on>2020-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-12</started-marketing-on>
      <ended-marketing-on>2017-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-816</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-21</started-marketing-on>
      <ended-marketing-on>2020-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021121</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-616</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211779</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-617</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211779</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-618</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211779</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211009</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-3310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211918</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-3311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211918</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-3312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211918</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-3313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211918</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-4576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on>2021-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-4577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on>2021-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-4578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-23</started-marketing-on>
      <ended-marketing-on>2021-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-527</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210992</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51407-528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210992</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-930</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204602</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-931</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204602</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-573</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-574</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-575</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207884</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206932</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206932</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206932</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Trigen Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13811-709</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Trigen Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13811-706</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Trigen Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13811-707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Trigen Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13811-708</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Trigen Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13811-710</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>72 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-042</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210992</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210992</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>2.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204115</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-571</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204115</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204115</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Granules Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70010-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>18 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-235</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-03</started-marketing-on>
      <ended-marketing-on>2018-08-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-23</started-marketing-on>
      <ended-marketing-on>2018-08-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5295</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5296</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077707</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078873</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078873</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078873</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3232</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5348</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA079031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-263</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-264</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-265</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-267</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-20</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-262</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-27</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200886</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-614</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-609</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA200886</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-610</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>51862-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078458</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Kremers Urban</labeller>
      <ndc-id/>
      <ndc-product-code>62175-151</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Kremers Urban</labeller>
      <ndc-id/>
      <ndc-product-code>62175-152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Kremers Urban</labeller>
      <ndc-id/>
      <ndc-product-code>62175-153</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Kremers Urban</labeller>
      <ndc-id/>
      <ndc-product-code>62175-154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Kremers Urban</labeller>
      <ndc-id/>
      <ndc-product-code>62175-155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Kremers Urban</labeller>
      <ndc-id/>
      <ndc-product-code>62175-156</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-4579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-4580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-4581</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-4582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-4583</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>methylphenidate hydrochloride CD</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0527-4584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021259</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride ER</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2018-10-16</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride ER</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-20</started-marketing-on>
      <ended-marketing-on>2018-10-16</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended Release</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207488</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended Release</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207488</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1810</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-1860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-0127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>27 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-0136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>36 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <labeller>SpecGx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0406-0154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>54 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Hydrochloride SR</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-03-31</started-marketing-on>
      <ended-marketing-on>2017-04-30</ended-marketing-on>
      <dosage-form>Tablet, film coated, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA018029</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Methylphenidate Tab 10mg</name>
      <labeller>Technilab Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00422975</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-06</started-marketing-on>
      <ended-marketing-on>1999-01-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Methylphenidate Tab 20mg</name>
      <labeller>Technilab Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00422983</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-06</started-marketing-on>
      <ended-marketing-on>1999-01-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-methylphenidate</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02274280</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-methylphenidate</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02274299</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-methylphenidate</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02274302</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-methylphenidate ER-C</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346214</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-methylphenidate ER-C</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346222</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-methylphenidate ER-C</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346230</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ntp-methylphenidate ER-C</name>
      <labeller>Nt Pharma Canada Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346249</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-methylphenidate</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126486</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-21</started-marketing-on>
      <ended-marketing-on>2003-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-methylphenidate</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-21</started-marketing-on>
      <ended-marketing-on>2003-04-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-methylphenidate</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246991</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-07</started-marketing-on>
      <ended-marketing-on>2003-01-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00584991</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00585009</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02234749</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate ER</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413728</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate ER</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413736</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate ER</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413744</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-methylphenidate ER</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413752</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>QuilliChew ER</name>
      <labeller>NextWave Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24478-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, Chewable, Extended Release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207960</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>QuilliChew ER</name>
      <labeller>NextWave Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24478-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, Chewable, Extended Release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207960</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>QuilliChew ER</name>
      <labeller>NextWave Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24478-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, Chewable, Extended Release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207960</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>QuilliChew ER</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-074</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, Chewable, Extended Release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207960</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>QuilliChew ER</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, Chewable, Extended Release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207960</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>QuilliChew ER</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, Chewable, Extended Release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207960</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>300 mg/60mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>600 mg/120mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-323</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>900 mg/180mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>750 mg/150mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>300 mg/60mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>600 mg/120mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>900 mg/180mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quillivant XR</name>
      <labeller>NextWave Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>24478-205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension, extended release</dosage-form>
      <strength>750 mg/150mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA202100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ratio-methylphenidate</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230321</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-22</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-methylphenidate</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230322</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-22</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-methylphenidate</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247364</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-01</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Relexxii</name>
      <labeller>Vertical Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68025-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>72 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205327</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1706</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2762</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>UNSPECIFIED</labeller>
      <ndc-id/>
      <ndc-product-code>0083-0007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-21</started-marketing-on>
      <ended-marketing-on>2006-02-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>UNSPECIFIED</labeller>
      <ndc-id/>
      <ndc-product-code>0083-0003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-21</started-marketing-on>
      <ended-marketing-on>2006-02-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>UNSPECIFIED</labeller>
      <ndc-id/>
      <ndc-product-code>0083-0034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-21</started-marketing-on>
      <ended-marketing-on>2006-02-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0440</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0441</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1955-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA010187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin 10mg</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00005606</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ritalin 20mg</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00005614</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>2019-11-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-05</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-05</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0658</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-01</started-marketing-on>
      <ended-marketing-on>2015-06-01</ended-marketing-on>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>60 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0370</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0371</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin LA</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0424</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, extended release</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021284</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin SR</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2418</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-03-31</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA018029</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin-SR</name>
      <labeller>UNSPECIFIED</labeller>
      <ndc-id/>
      <ndc-product-code>0083-0016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-21</started-marketing-on>
      <ended-marketing-on>2006-02-21</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin-SR</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0442</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-24</started-marketing-on>
      <ended-marketing-on>2007-04-24</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ritalin-SR Tab 20mg</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00632775</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Methylphenidate</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455846</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Methylphenidate</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455854</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Methylphenidate SR</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320312</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-methylphenidate ER-C</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315068</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-methylphenidate ER-C</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315076</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-methylphenidate ER-C</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315084</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-methylphenidate ER-C</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315092</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Equasym XL</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Medikinet XL</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Quillivant</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Riphenidate</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Rubifen SR</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Metadate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin SR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Cotempla XR-ODT</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Cotempla XR-ODT</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Cotempla XR-ODT</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin-SR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>QuilliChew ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>QuilliChew ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>QuilliChew ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>QuilliChew ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>QuilliChew ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>QuilliChew ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Quillivant XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate HCl Oral Solution</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate HCl Oral Solution</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin-SR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>methylphenidate hydrochloride CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>JORNAY PM Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>JORNAY PM Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>JORNAY PM Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>JORNAY PM Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>JORNAY PM Extended-Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Aptensio XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Adhansia XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Adhansia XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Adhansia XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Adhansia XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Adhansia XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Adhansia XR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Metadate CD</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride SR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Relexxii</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin LA</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Daytrana</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (CD)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride Extended Release</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride (LA)</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Hydrochloride</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin-SR Tab 20mg</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Concerta</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate SR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Biphentin</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin 10mg</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ritalin 20mg</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Methylphenidate SR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PMS-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Tab 10mg</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Methylphenidate Tab 20mg</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Novo-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Novo-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Novo-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ntp-methylphenidate ER-C</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PHL-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PHL-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>PHL-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-methylphenidate</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Foquest</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Act Methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Act Methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Act Methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Act Methylphenidate ER</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
    <mixture>
      <name>Bar-methylphenidate HCl CR</name>
      <ingredients>Methylphenidate</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Alliant Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Alza Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Apothecon</name>
      <url>http://www.apothecon.nl</url>
    </packager>
    <packager>
      <name>Bryant Ranch Prepack</name>
      <url>http://bryantranchprepack.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Caremark LLC</name>
      <url>http://www.caremark.com</url>
    </packager>
    <packager>
      <name>Chattem Chemicals Inc.</name>
      <url>http://www.chattem.com</url>
    </packager>
    <packager>
      <name>D.M. Graham Laboratories Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Elan Pharmaceuticals Inc.</name>
      <url>http://www.elan.com</url>
    </packager>
    <packager>
      <name>Eurand Pharmaceuticals Inc.</name>
      <url>http://www.eurand.com</url>
    </packager>
    <packager>
      <name>Janssen-Ortho Inc.</name>
      <url>http://www.janssen-ortho.com</url>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Mallinckrodt Inc.</name>
      <url>http://www.mallinckrodt.com</url>
    </packager>
    <packager>
      <name>Mckesson Corp.</name>
      <url>http://www.mckesson.com</url>
    </packager>
    <packager>
      <name>McNeil Laboratories</name>
      <url/>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Noven Pharmaceuticals Inc.</name>
      <url>http://www.noven.com</url>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Ortho Mcneil Janssen Pharmaceutical Inc.</name>
      <url>http://www.ortho-mcneil.com</url>
    </packager>
    <packager>
      <name>Patriot Pharmaceuticals</name>
      <url>http://www.patriotpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Purdue Pharma LP</name>
      <url>http://www.purduepharma.com</url>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Quality Care</name>
      <url/>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Sciele Pharma Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Shire Inc.</name>
      <url>http://www.shire.com</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
    <packager>
      <name>Superior Pharmeceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>UCB Pharma</name>
      <url>http://www.ucb.com</url>
    </packager>
    <packager>
      <name>Upstate Pharma LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Shire development inc</manufacturer>
    <manufacturer generic="false" url="">Ucb inc</manufacturer>
    <manufacturer generic="false" url="">Novartis pharmaceuticals corp</manufacturer>
    <manufacturer generic="false" url="">Mallinckrodt inc</manufacturer>
    <manufacturer generic="true" url="">Tris pharma inc</manufacturer>
    <manufacturer generic="false" url="">Ortho mcneil janssen pharmaceutical inc</manufacturer>
    <manufacturer generic="true" url="">Able laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Actavis elizabeth llc</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
    <manufacturer generic="false" url="">Ortho-McNeil-Janssen Pharmaceuticals, Inc.</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Methylin ER 10 mg</description>
      <cost currency="USD">1.0</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Methylphenidate HCl 20 mg tablet</description>
      <cost currency="USD">1.05</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylin er 20 mg tablet</description>
      <cost currency="USD">1.12</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate HCl CR 20 mg Controlled Release Tabs</description>
      <cost currency="USD">1.2</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Focalin 5 mg tablet</description>
      <cost currency="USD">1.26</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Metadate er 10 mg tablet sa</description>
      <cost currency="USD">1.28</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin 10 mg tablet</description>
      <cost currency="USD">1.29</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylin ER 20 mg Controlled Release Tabs</description>
      <cost currency="USD">1.3</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Metadate er 20 mg tablet</description>
      <cost currency="USD">1.32</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin 5 mg tablet</description>
      <cost currency="USD">1.42</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Focalin 10 mg tablet</description>
      <cost currency="USD">1.7</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin 20 mg tablet</description>
      <cost currency="USD">1.87</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin sr 20 mg tablet</description>
      <cost currency="USD">2.67</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin SR 20 mg Controlled Release Tabs</description>
      <cost currency="USD">3.0</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Methylphenidate er 10 mg tablet</description>
      <cost currency="USD">3.24</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Metadate cd 10 mg capsule</description>
      <cost currency="USD">4.2</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Metadate cd 20 mg capsule</description>
      <cost currency="USD">4.24</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Metadate cd 30 mg capsule</description>
      <cost currency="USD">4.24</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 18 mg tablet sa</description>
      <cost currency="USD">4.27</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin la 10 mg capsule</description>
      <cost currency="USD">4.33</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ritalin la 20 mg capsule</description>
      <cost currency="USD">4.33</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 27 mg tablet sa</description>
      <cost currency="USD">4.37</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin LA 10 mg 24 Hour Capsule</description>
      <cost currency="USD">4.42</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ritalin LA 20 mg 24 Hour Capsule</description>
      <cost currency="USD">4.42</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ritalin LA 30 mg 24 Hour Capsule</description>
      <cost currency="USD">4.42</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ritalin LA 40 mg 24 Hour Capsule</description>
      <cost currency="USD">4.42</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Ritalin la 30 mg capsule</description>
      <cost currency="USD">4.43</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 36 mg tablet sa</description>
      <cost currency="USD">4.51</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin la 40 mg capsule</description>
      <cost currency="USD">4.55</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin XR 5 mg 24 Hour Capsule</description>
      <cost currency="USD">4.83</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin XR 15 mg 24 Hour Capsule</description>
      <cost currency="USD">4.89</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 54 mg tablet sa</description>
      <cost currency="USD">4.91</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Focalin xr 5 mg capsule</description>
      <cost currency="USD">4.95</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin XR 10 mg 24 Hour Capsule</description>
      <cost currency="USD">4.96</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 18 mg Controlled Release Tabs</description>
      <cost currency="USD">5.0</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Concerta 27 mg Controlled Release Tabs</description>
      <cost currency="USD">5.0</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Focalin xr 10 mg capsule</description>
      <cost currency="USD">5.02</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin XR 30 mg 24 Hour Capsule</description>
      <cost currency="USD">5.15</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Daytrana 10 mg/9 hr patch</description>
      <cost currency="USD">5.16</cost>
      <unit>patch</unit>
    </price>
    <price>
      <description>Daytrana 15 mg/9 hr patch</description>
      <cost currency="USD">5.16</cost>
      <unit>patch</unit>
    </price>
    <price>
      <description>Daytrana 20 mg/9 hour patch</description>
      <cost currency="USD">5.16</cost>
      <unit>patch</unit>
    </price>
    <price>
      <description>Daytrana 30 mg/9 hour patch</description>
      <cost currency="USD">5.16</cost>
      <unit>patch</unit>
    </price>
    <price>
      <description>Focalin xr 15 mg capsule</description>
      <cost currency="USD">5.16</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin xr 20 mg capsule</description>
      <cost currency="USD">5.16</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin XR 20 mg 24 Hour Capsule</description>
      <cost currency="USD">5.31</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Focalin xr 30 mg capsule</description>
      <cost currency="USD">5.42</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 36 mg Controlled Release Tabs</description>
      <cost currency="USD">5.72</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Metadate cd 40 mg capsule</description>
      <cost currency="USD">5.77</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta 54 mg Controlled Release Tabs</description>
      <cost currency="USD">6.18</cost>
      <unit>tab</unit>
    </price>
    <price>
      <description>Metadate cd 60 mg capsule</description>
      <cost currency="USD">7.02</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Metadate cd 50 mg capsule</description>
      <cost currency="USD">7.08</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Concerta er 18 mg tablet</description>
      <cost currency="USD">22.11</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Concerta er 27 mg tablet</description>
      <cost currency="USD">22.65</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Concerta er 36 mg tablet</description>
      <cost currency="USD">23.38</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Concerta er 54 mg tablet</description>
      <cost currency="USD">25.45</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate hcl powder</description>
      <cost currency="USD">44.62</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Daytrana 30 20 mg/9hr Patches Box</description>
      <cost currency="USD">168.72</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Daytrana 30 10 mg/9hr Patches Box</description>
      <cost currency="USD">172.78</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Daytrana 30 30 mg/9hr Patches Box</description>
      <cost currency="USD">174.73</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Daytrana 30 15 mg/9hr Patches Box</description>
      <cost currency="USD">175.64</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Pms-Methylphenidate 5 mg Tablet</description>
      <cost currency="USD">0.1</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Methylphenidate 10 mg Tablet</description>
      <cost currency="USD">0.17</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Methylphenidate 10 mg Tablet</description>
      <cost currency="USD">0.17</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylin 5 mg tablet</description>
      <cost currency="USD">0.33</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate 5 mg tablet</description>
      <cost currency="USD">0.33</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Methylphenidate 20 mg Tablet</description>
      <cost currency="USD">0.37</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Methylphenidate Sr 20 mg Extended-Release Tablet</description>
      <cost currency="USD">0.37</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Methylphenidate 20 mg Tablet</description>
      <cost currency="USD">0.37</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Sandoz Methylphenidate 20 mg Extended-Release Tablet</description>
      <cost currency="USD">0.37</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin 10 mg Tablet</description>
      <cost currency="USD">0.38</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylin 10 mg tablet</description>
      <cost currency="USD">0.48</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate 10 mg tablet</description>
      <cost currency="USD">0.48</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin 20 mg Tablet</description>
      <cost currency="USD">0.67</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ritalin Sr 20 mg Extended-Release Tablet</description>
      <cost currency="USD">0.67</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylin 20 mg tablet</description>
      <cost currency="USD">0.69</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate 20 mg tablet</description>
      <cost currency="USD">0.69</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Focalin 2.5 mg tablet</description>
      <cost currency="USD">0.76</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylin er 10 mg tablet</description>
      <cost currency="USD">0.84</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate HCl 5 mg tablet</description>
      <cost currency="USD">0.94</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Methylphenidate HCl 10 mg tablet</description>
      <cost currency="USD">0.95</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Agents that produce hypertension</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents that reduce seizure threshold</category>
      <mesh-id/>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Stimulants</category>
      <mesh-id>D000697</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Stimulation</category>
      <mesh-id/>
    </category>
    <category>
      <category>Centrally Acting Sympathomimetics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dopamine Agents</category>
      <mesh-id>D015259</mesh-id>
    </category>
    <category>
      <category>Dopamine Uptake Inhibitors</category>
      <mesh-id>D018765</mesh-id>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Membrane Transport Modulators</category>
      <mesh-id>D049990</mesh-id>
    </category>
    <category>
      <category>Methylphenidate and isomer</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Uptake Inhibitors</category>
      <mesh-id>D014179</mesh-id>
    </category>
    <category>
      <category>Phenylacetates</category>
      <mesh-id>D010648</mesh-id>
    </category>
    <category>
      <category>Piperidines</category>
      <mesh-id>D010880</mesh-id>
    </category>
    <category>
      <category>Psychoanaleptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychostimulants, Agents Used for Adhd and Nootropics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Respiratory and CNS Stimulants</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>35 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>45 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>55 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>70 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>85 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>15 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>18 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>18 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>27 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>27 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>36 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>36 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>54 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>54 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>17.3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>25.9 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>8.6 mg/1</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>10 mg/9h</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>15 mg/9h</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>20 mg/9h</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>30 mg/9h</strength>
    </dosage>
    <dosage>
      <form/>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>80 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>30 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength>2.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>10 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>2 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>5 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>18 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>27 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>18 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>27 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>36 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>54 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, extended release</form>
      <route>Oral</route>
      <strength>60 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>30 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>60 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>36 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>54 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated, extended release</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, chewable, extended release</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, chewable, extended release</form>
      <route>Oral</route>
      <strength>30 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, chewable, extended release</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Suspension, extended release</form>
      <route>Oral</route>
      <strength>300 mg/60mL</strength>
    </dosage>
    <dosage>
      <form>Suspension, extended release</form>
      <route>Oral</route>
      <strength>600 mg/120mL</strength>
    </dosage>
    <dosage>
      <form>Suspension, extended release</form>
      <route>Oral</route>
      <strength>750 mg/150mL</strength>
    </dosage>
    <dosage>
      <form>Suspension, extended release</form>
      <route>Oral</route>
      <strength>900 mg/180mL</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength>72 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N06BA04">
      <level code="N06BA">Centrally acting sympathomimetics</level>
      <level code="N06B">PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS</level>
      <level code="N06">PSYCHOANALEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:20.32</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents>
    <patent>
      <number>5958446</number>
      <country>United States</country>
      <approved>1999-09-28</approved>
      <expires>2012-12-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2355644</number>
      <country>Canada</country>
      <approved>2009-01-20</approved>
      <expires>2019-12-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2264852</number>
      <country>Canada</country>
      <approved>2005-11-01</approved>
      <expires>2017-09-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8999386</number>
      <country>United States</country>
      <approved>2015-04-07</approved>
      <expires>2033-04-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6919373</number>
      <country>United States</country>
      <approved>2005-07-19</approved>
      <expires>2018-01-31</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6930129</number>
      <country>United States</country>
      <approved>2005-08-16</approved>
      <expires>2018-01-31</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9000038</number>
      <country>United States</country>
      <approved>2015-04-07</approved>
      <expires>2018-01-31</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9144549</number>
      <country>United States</country>
      <approved>2015-09-29</approved>
      <expires>2017-07-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9029416</number>
      <country>United States</country>
      <approved>2015-05-12</approved>
      <expires>2017-07-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8163798</number>
      <country>United States</country>
      <approved>2012-04-24</approved>
      <expires>2018-01-31</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8629179</number>
      <country>United States</country>
      <approved>2014-01-14</approved>
      <expires>2018-01-31</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6344215</number>
      <country>United States</country>
      <approved>2002-02-05</approved>
      <expires>2020-10-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6228398</number>
      <country>United States</country>
      <approved>2001-05-08</approved>
      <expires>2019-11-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6635284</number>
      <country>United States</country>
      <approved>2003-10-21</approved>
      <expires>2015-12-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7431944</number>
      <country>United States</country>
      <approved>2008-10-07</approved>
      <expires>2015-12-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5837284</number>
      <country>United States</country>
      <approved>1998-11-17</approved>
      <expires>2015-12-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7691880</number>
      <country>United States</country>
      <approved>2010-04-06</approved>
      <expires>2024-10-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6210705</number>
      <country>United States</country>
      <approved>2001-04-03</approved>
      <expires>2018-09-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6348211</number>
      <country>United States</country>
      <approved>2002-02-19</approved>
      <expires>2018-09-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8632802</number>
      <country>United States</country>
      <approved>2014-01-21</approved>
      <expires>2025-10-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9034370</number>
      <country>United States</country>
      <approved>2015-05-19</approved>
      <expires>2025-10-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8062667</number>
      <country>United States</country>
      <approved>2011-11-22</approved>
      <expires>2029-03-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8465765</number>
      <country>United States</country>
      <approved>2013-06-18</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8778390</number>
      <country>United States</country>
      <approved>2014-07-15</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8563033</number>
      <country>United States</country>
      <approved>2013-10-22</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8956649</number>
      <country>United States</country>
      <approved>2015-02-17</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9040083</number>
      <country>United States</country>
      <approved>2015-05-26</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8287903</number>
      <country>United States</country>
      <approved>2012-10-16</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9295642</number>
      <country>United States</country>
      <approved>2016-03-29</approved>
      <expires>2033-08-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8202537</number>
      <country>United States</country>
      <approved>2012-06-19</approved>
      <expires>2027-03-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7438930</number>
      <country>United States</country>
      <approved>2008-10-21</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9066869</number>
      <country>United States</country>
      <approved>2015-06-30</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7247318</number>
      <country>United States</country>
      <approved>2007-07-24</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7083808</number>
      <country>United States</country>
      <approved>2006-08-01</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6419960</number>
      <country>United States</country>
      <approved>2002-07-16</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8580310</number>
      <country>United States</country>
      <approved>2013-11-12</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8840924</number>
      <country>United States</country>
      <approved>2014-09-23</approved>
      <expires>2026-06-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9668981</number>
      <country>United States</country>
      <approved>2017-06-06</approved>
      <expires>2025-10-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9545399</number>
      <country>United States</country>
      <approved>2017-01-17</approved>
      <expires>2033-08-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9089496</number>
      <country>United States</country>
      <approved>2015-07-28</approved>
      <expires>2032-06-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9072680</number>
      <country>United States</country>
      <approved>2015-07-07</approved>
      <expires>2032-06-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9844544</number>
      <country>United States</country>
      <approved>2017-12-19</approved>
      <expires>2033-08-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9801823</number>
      <country>United States</country>
      <approved>2017-10-31</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>10039719</number>
      <country>United States</country>
      <approved>2018-08-07</approved>
      <expires>2020-06-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9498447</number>
      <country>United States</country>
      <approved>2016-11-22</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9283214</number>
      <country>United States</country>
      <approved>2016-03-15</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9023389</number>
      <country>United States</country>
      <approved>2015-05-05</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8927010</number>
      <country>United States</country>
      <approved>2015-01-06</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9028868</number>
      <country>United States</country>
      <approved>2015-05-12</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9034902</number>
      <country>United States</country>
      <approved>2015-05-19</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9603809</number>
      <country>United States</country>
      <approved>2017-03-28</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8916588</number>
      <country>United States</country>
      <approved>2014-12-23</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10182995</number>
      <country>United States</country>
      <approved>2019-01-22</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10111839</number>
      <country>United States</country>
      <approved>2018-10-30</approved>
      <expires>2035-10-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9974752</number>
      <country>United States</country>
      <approved>2018-05-22</approved>
      <expires>2035-10-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10292939</number>
      <country>United States</country>
      <approved>2019-05-21</approved>
      <expires>2035-10-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10292938</number>
      <country>United States</country>
      <approved>2019-05-21</approved>
      <expires>2035-10-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10292937</number>
      <country>United States</country>
      <approved>2019-05-21</approved>
      <expires>2032-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
    <food-interaction>Avoid excessive quantities of coffee or tea (Caffeine).</food-interaction>
    <food-interaction>Take on empty stomach: 1 hour before or 2 hours after meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Remikiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bethanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanadrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Olmesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nitroprusside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Minoxidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Treprostinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Candoxatril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Phentolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cryptenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Tolazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Fenoldopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Tadalafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Omapatrilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Deserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bretylium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Saprisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Tienilic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Sitaxentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Ambrisentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Diethylnorspermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Pinacidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Riociguat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Macitentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Indoramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Trimazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Nicorandil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Moxonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Rauwolfia serpentina root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Selexipag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Angiotensin 1-7.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Rilmenidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>Methylphenidate may decrease the antihypertensive activities of BQ-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Urapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cicletanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Dihydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Vincamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Linsidomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanoxabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Tolonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Endralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cadralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Bietaserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanazodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Methoserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Guanoclor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Muzolimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Xipamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Methylphenidate may decrease the antihypertensive activities of Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of hypertension can be increased when Phentermine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The risk or severity of hypertension can be increased when Midodrine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The risk or severity of hypertension can be increased when Eletriptan is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>The risk or severity of hypertension can be increased when Isoetharine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>The risk or severity of hypertension can be increased when Methysergide is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of hypertension can be increased when Zolmitriptan is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>The risk or severity of hypertension can be increased when Methylergometrine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The risk or severity of hypertension can be increased when Norepinephrine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The risk or severity of hypertension can be increased when Mirtazapine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The risk or severity of hypertension can be increased when Phenylephrine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00561</drugbank-id>
      <name>Doxapram</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Doxapram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Metaraminol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Nicergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Methoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Orciprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Phenmetrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Benzphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ritodrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Bitolterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxymetazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Salmeterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Naratriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Formoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Frovatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergoloid mesylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Arbutamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01126</drugbank-id>
      <name>Dutasteride</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dutasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01216</drugbank-id>
      <name>Finasteride</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Finasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Pirbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ephedra sinica root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Procaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Clenbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01579</drugbank-id>
      <name>Phendimetrazine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Phendimetrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02032</drugbank-id>
      <name>1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04581</drugbank-id>
      <name>1-benzylimidazole</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 1-benzylimidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Lysergic acid diethylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Indacaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05395</drugbank-id>
      <name>Amibegron</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Amibegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Naluzotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06190</drugbank-id>
      <name>Solabegron</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Solabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Xylometazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Isometheptene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06707</drugbank-id>
      <name>Levonordefrin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Levonordefrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Naphazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Saralasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tetryzoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Cinitapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08925</drugbank-id>
      <name>Adrafinil</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Adrafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Hexoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Etilefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Olodaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09202</drugbank-id>
      <name>Cirazoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Cirazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Synephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Doxofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Iofetamine I-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Racepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dihydroergocornine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11373</drugbank-id>
      <name>Amitraz</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Amitraz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11481</drugbank-id>
      <name>Atipamezole</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Atipamezole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11541</drugbank-id>
      <name>Ractopamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ractopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tetrahydrocannabivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with PF-00610355.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Abediterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12248</drugbank-id>
      <name>Tulobuterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tulobuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dopexamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Piclozotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12551</drugbank-id>
      <name>Idazoxan</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Idazoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Higenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12846</drugbank-id>
      <name>Reproterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Reproterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Theodrenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tramazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13251</drugbank-id>
      <name>Octopamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Octopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Fenozolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Dihydroergocristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13378</drugbank-id>
      <name>Norfenefrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Norfenefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13398</drugbank-id>
      <name>Oxyfedrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Oxyfedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13399</drugbank-id>
      <name>Terguride</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Terguride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Buflomedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Metergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13559</drugbank-id>
      <name>Rimiterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Rimiterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Methoxyphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Tretoquinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Gepefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Prenalterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13781</drugbank-id>
      <name>Xamoterol</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Xamoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Mefenorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13917</drugbank-id>
      <name>Deoxyepinephrine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Deoxyepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with 5-methoxy-N,N-dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>Aluminium can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>Sodium bicarbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Aluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>Calcium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>Magaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Bismuth subnitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>Magnesium silicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>Aluminium acetoacetate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>Hydrotalcite can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>Magnesium peroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>Aluminium glycinate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>Aloglutamol can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>Calcium silicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>Aluminium phosphate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>Omeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>Lansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>Esomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>Dexrabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15246</drugbank-id>
      <name>Salvianolic acid A</name>
      <description>Salvianolic acid A can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of adverse effects can be increased when Amoxapine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of adverse effects can be increased when Moricizine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>The risk or severity of adverse effects can be increased when Acetophenazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>The risk or severity of adverse effects can be increased when Alimemazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The risk or severity of adverse effects can be increased when Periciazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>The risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>The risk or severity of adverse effects can be increased when Bifeprunox is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>The risk or severity of adverse effects can be increased when BL-1020 is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The risk or severity of adverse effects can be increased when Cariprazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The risk or severity of adverse effects can be increased when Lumateperone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The risk or severity of adverse effects can be increased when Perospirone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>The risk or severity of adverse effects can be increased when Amperozide is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>The risk or severity of adverse effects can be increased when Blonanserin is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The risk or severity of adverse effects can be increased when Zotepine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>The risk or severity of adverse effects can be increased when RP-5063 is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The risk or severity of adverse effects can be increased when Azaperone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>The risk or severity of adverse effects can be increased when Propiopromazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The risk or severity of adverse effects can be increased when Ecopipam is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The risk or severity of adverse effects can be increased when Bromperidol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The risk or severity of adverse effects can be increased when Raclopride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of adverse effects can be increased when Ritanserin is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of adverse effects can be increased when Perazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The risk or severity of adverse effects can be increased when Benperidol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>The risk or severity of adverse effects can be increased when Prothipendyl is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>The risk or severity of adverse effects can be increased when Butaperazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>The risk or severity of adverse effects can be increased when Clothiapine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of adverse effects can be increased when Sultopride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>The risk or severity of adverse effects can be increased when Oxypertine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>The risk or severity of adverse effects can be increased when Thiazinam is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>The risk or severity of adverse effects can be increased when Veralipride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>The risk or severity of adverse effects can be increased when Trifluperidol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>The risk or severity of adverse effects can be increased when Moperone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>The risk or severity of adverse effects can be increased when Thiopropazate is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>The risk or severity of adverse effects can be increased when Fluanisone is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>The risk or severity of adverse effects can be increased when Mosapramine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>The risk or severity of adverse effects can be increased when Dixyrazine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of adverse effects can be increased when Penfluridol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Clopenthixol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Carbidopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tolcapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Entacapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Lisuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Progabide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Memantine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02105</drugbank-id>
      <name>3,5-Dinitrocatechol</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with 3,5-Dinitrocatechol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06535</drugbank-id>
      <name>Etilevodopa</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Etilevodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ifenprodil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11632</drugbank-id>
      <name>Opicapone</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opicapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12478</drugbank-id>
      <name>Piribedil</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Piribedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Benserazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13313</drugbank-id>
      <name>Melevodopa</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Melevodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dihydroergocryptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13502</drugbank-id>
      <name>Budipine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Budipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15130</drugbank-id>
      <name>Dexpramipexole</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dexpramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Methylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The serum concentration of Primidone can be increased when it is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The serum concentration of Methylphenobarbital can be increased when it is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Nizatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Famotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08805</drugbank-id>
      <name>Metiamide</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Metiamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08806</drugbank-id>
      <name>Roxatidine acetate</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Roxatidine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12770</drugbank-id>
      <name>Lafutidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Lafutidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12884</drugbank-id>
      <name>Lavoltidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Lavoltidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13760</drugbank-id>
      <name>Niperotidine</name>
      <description>The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Niperotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The metabolism of Dicoumarol can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The metabolism of Phenindione can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The metabolism of Phenprocoumon can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The metabolism of 4-hydroxycoumarin can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The metabolism of Coumarin can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The metabolism of Ethyl biscoumacetate can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The metabolism of Fluindione can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The metabolism of Clorindione can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The metabolism of Diphenadione can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The metabolism of Tioclomarol can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The metabolism of (S)-Warfarin can be decreased when combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>Methylphenidate may increase the hypertensive activities of Enflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Methylphenidate may increase the hypertensive activities of Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>Methylphenidate may increase the hypertensive activities of Methoxyflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>Methylphenidate may increase the hypertensive activities of Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Methylphenidate may increase the hypertensive activities of Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Methylphenidate may increase the hypertensive activities of Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>Methylphenidate may increase the hypertensive activities of Nitrous oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>Methylphenidate may increase the hypertensive activities of Trichloroethylene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>Methylphenidate may increase the hypertensive activities of Xenon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Methylphenidate may increase the hypertensive activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>Icosapent may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>Cefotiam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>Cefmenoxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>Cefmetazole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>Pamidronic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>Tenofovir disoproxil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>Cidofovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Triamterene may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>Cefpiramide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>Ceftazidime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>Loracarbef may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Framycetin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>Cefalotin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Amikacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>Cefotaxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>Foscarnet may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Methotrexate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>Cephalexin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>Valaciclovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00626</drugbank-id>
      <name>Bacitracin</name>
      <description>Bacitracin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>Amphotericin B may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Tobramycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>Cephaloglycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Flurbiprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>Adefovir dipivoxil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Pentamidine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>Mannitol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>Acyclovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Gentamicin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Cefaclor may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Etacrynic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>Ceforanide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Netilmicin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>Carboplatin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Neomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ibuprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>Cefditoren may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Atazanavir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Streptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>Colistimethate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>Cefuroxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>Cefapirin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>Cefadroxil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>Cefprozil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Kanamycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>Ceftriaxone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>Cefamandole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>Cefazolin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>Cefonicid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>Cefoperazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>Cefotetan may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>Cefoxitin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>Ceftizoxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>Cefradine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Choline magnesium trisalicylate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>Cefepime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>Cefacetrile may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>Ceftibuten may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>Cefpodoxime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>Antrafenine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Paromomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>Aminophenazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Lopinavir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02247</drugbank-id>
      <name>Hydrolyzed Cephalothin</name>
      <description>Hydrolyzed Cephalothin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03450</drugbank-id>
      <name>Cephalothin Group</name>
      <description>Cephalothin Group may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Ribostamycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Geneticin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>Niflumic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>Latamoxef may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Apramycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>Gentamicin C1a may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Neamine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>Ceftobiprole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>Cimicoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>Ceftaroline fosamil may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Arbekacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>Felbinac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Puromycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>Cefaloridine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>Cefminox may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>Benzydamine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>Dexibuprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>Dexketoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>Tolfenamic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>Firocoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>Morniflumate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>Talniflumate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>Tenofovir alafenamide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>Cefroxadine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>Robenacoxib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Dihydrostreptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Hygromycin B may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>Flomoxef may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>Brincidofovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Sisomicin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>Alclofenac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>Fentiazac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>Suxibuzone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>Cefatrizine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>Dibekacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>Micronomicin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>Bumadizone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>Alminoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>Flunoxaprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>Feprazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>Difenpiramide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>Nifenazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>Lonazolac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>Cefcapene may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>Cefodizime may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>Tenidap may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>Cefsulodin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>Bendazac may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>Cefetamet may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>Pranoprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>Propyphenazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>Proglumetacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>Isepamicin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>Ethenzamide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>Mofebutazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>Cefbuperazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>Proquazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>Benorilate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>Cefozopran may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>Bekanamycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>Cefpirome may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>Pirprofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>Cefazedone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>Acemetacin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>Ceftezole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>Imidazole salicylate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13868</drugbank-id>
      <name>Adefovir</name>
      <description>Adefovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>SC-236 may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>NS-398 may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>Tenofovir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>Inotersen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>Phenazopyridine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>Givosiran may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Leuprolide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Goserelin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>Salmon Calcitonin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Desmopressin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Aldesleukin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>Daptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>Tositumomab may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>Cyanocobalamin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Folic acid may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00165</drugbank-id>
      <name>Pyridoxine</name>
      <description>Pyridoxine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>Baclofen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>Cevimeline may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Lorazepam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>Tramadol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Fluconazole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>Oseltamivir may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00200</drugbank-id>
      <name>Hydroxocobalamin</name>
      <description>Hydroxocobalamin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Pantoprazole may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00225</drugbank-id>
      <name>Gadodiamide</name>
      <description>Gadodiamide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Pregabalin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Temazepam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Butabarbital may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>Ranolazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Doxycycline may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>Carmustine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>Diatrizoate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>Topiramate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Liothyronine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Disopyramide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Acarbose may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>Bleomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Etomidate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Etonogestrel may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00303</drugbank-id>
      <name>Ertapenem</name>
      <description>Ertapenem may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Ibutilide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Acetaminophen may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>Piperacillin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>Floxuridine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>Hydromorphone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00330</drugbank-id>
      <name>Ethambutol</name>
      <description>Ethambutol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Metformin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Methadone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>Pyrazinamide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>Cetirizine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>Clobazam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>Megestrol acetate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00355</drugbank-id>
      <name>Aztreonam</name>
      <description>Aztreonam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Chlorzoxazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Sulfadiazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Sucralfate may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Palonosetron may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>Dexrazoxane may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>Sorafenib may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>Eszopiclone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>Alprazolam may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>Ampicillin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may decrease the excretion rate of Methylphenidate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>Methylphenidate may decrease the excretion rate of Trifluridine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Methylphenidate may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Methylphenidate may decrease the excretion rate of Allopurinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>Methylphenidate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>Methylphenidate may decrease the excretion rate of Gemcitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Methylphenidate may decrease the excretion rate of Duloxetine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Methylphenidate may decrease the excretion rate of Lenalidomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>Methylphenidate may decrease the excretion rate of Buspirone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>Methylphenidate may decrease the excretion rate of Flutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Methylphenidate may decrease the excretion rate of Cefdinir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Methylphenidate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00548</drugbank-id>
      <name>Azelaic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Azelaic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>Methylphenidate may decrease the excretion rate of Pentostatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Methylphenidate may decrease the excretion rate of Methoxsalen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>Methylphenidate may decrease the excretion rate of Lamotrigine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00558</drugbank-id>
      <name>Zanamivir</name>
      <description>Methylphenidate may decrease the excretion rate of Zanamivir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Methylphenidate may decrease the excretion rate of Fondaparinux which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>Methylphenidate may decrease the excretion rate of Levocarnitine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Methylphenidate may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00597</drugbank-id>
      <name>Gadoteridol</name>
      <description>Methylphenidate may decrease the excretion rate of Gadoteridol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>Methylphenidate may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Methylphenidate may decrease the excretion rate of Chloroquine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Methylphenidate may decrease the excretion rate of Testosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Methylphenidate may decrease the excretion rate of Clofarabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Methylphenidate may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Methylphenidate may decrease the excretion rate of Prednisone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>Methylphenidate may decrease the excretion rate of Dyphylline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Methylphenidate may decrease the excretion rate of Metaxalone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>Methylphenidate may decrease the excretion rate of Verapamil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>Methylphenidate may decrease the excretion rate of Nilutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Methylphenidate may decrease the excretion rate of Sumatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Methylphenidate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Methylphenidate may decrease the excretion rate of Galantamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>Methylphenidate may decrease the excretion rate of Midazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Methylphenidate may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>Methylphenidate may decrease the excretion rate of Flurazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Methylphenidate may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Methylphenidate may decrease the excretion rate of Tamsulosin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Methylphenidate may decrease the excretion rate of Lamivudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>Methylphenidate may decrease the excretion rate of Oxacillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00716</drugbank-id>
      <name>Nedocromil</name>
      <description>Methylphenidate may decrease the excretion rate of Nedocromil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>Methylphenidate may decrease the excretion rate of Thiabendazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Methylphenidate may decrease the excretion rate of Nateglinide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00733</drugbank-id>
      <name>Pralidoxime</name>
      <description>Methylphenidate may decrease the excretion rate of Pralidoxime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Methylphenidate may decrease the excretion rate of Tetracycline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00760</drugbank-id>
      <name>Meropenem</name>
      <description>Methylphenidate may decrease the excretion rate of Meropenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>Methylphenidate may decrease the excretion rate of Potassium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Methylphenidate may decrease the excretion rate of Methimazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Methylphenidate may decrease the excretion rate of Tirofiban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Methylphenidate may decrease the excretion rate of Propantheline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Methylphenidate may decrease the excretion rate of Estradiol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00789</drugbank-id>
      <name>Gadopentetic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Methylphenidate may decrease the excretion rate of Dicyclomine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Methylphenidate may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Methylphenidate may decrease the excretion rate of Ribavirin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00828</drugbank-id>
      <name>Fosfomycin</name>
      <description>Methylphenidate may decrease the excretion rate of Fosfomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>Methylphenidate may decrease the excretion rate of Diazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Methylphenidate may decrease the excretion rate of Tolazamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>Methylphenidate may decrease the excretion rate of Dobutamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Methylphenidate may decrease the excretion rate of Oxazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>Methylphenidate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>Methylphenidate may decrease the excretion rate of Temozolomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Methylphenidate may decrease the excretion rate of Terbutaline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Methylphenidate may decrease the excretion rate of Bumetanide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>Methylphenidate may decrease the excretion rate of Testolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>Methylphenidate may decrease the excretion rate of Triazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Methylphenidate may decrease the excretion rate of Didanosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Methylphenidate may decrease the excretion rate of Zonisamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Methylphenidate may decrease the excretion rate of Tinidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Methylphenidate may decrease the excretion rate of Almotriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>Methylphenidate may decrease the excretion rate of Azacitidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Methylphenidate may decrease the excretion rate of Maprotiline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>Methylphenidate may decrease the excretion rate of Isoniazid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Methylphenidate may decrease the excretion rate of Rizatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Methylphenidate may decrease the excretion rate of Mepivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Methylphenidate may decrease the excretion rate of Zaleplon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>Methylphenidate may decrease the excretion rate of Ramelteon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>Methylphenidate may decrease the excretion rate of Dopamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>Methylphenidate may decrease the excretion rate of Azathioprine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00995</drugbank-id>
      <name>Auranofin</name>
      <description>Methylphenidate may decrease the excretion rate of Auranofin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Methylphenidate may decrease the excretion rate of Salbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Methylphenidate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>Methylphenidate may decrease the excretion rate of Ganciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>Methylphenidate may decrease the excretion rate of Edrophonium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>Methylphenidate may decrease the excretion rate of Metyrapone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Methylphenidate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Methylphenidate may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01022</drugbank-id>
      <name>Phylloquinone</name>
      <description>Methylphenidate may decrease the excretion rate of Phylloquinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>Methylphenidate may decrease the excretion rate of Topotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>Methylphenidate may decrease the excretion rate of Probenecid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Methylphenidate may decrease the excretion rate of Tolterodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>Methylphenidate may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>Methylphenidate may decrease the excretion rate of Lubiprostone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>Methylphenidate may decrease the excretion rate of Abacavir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>Methylphenidate may decrease the excretion rate of Amoxicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Methylphenidate may decrease the excretion rate of Glipizide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Methylphenidate may decrease the excretion rate of Clonazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Methylphenidate may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>Methylphenidate may decrease the excretion rate of Flucytosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>Methylphenidate may decrease the excretion rate of Capecitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Methylphenidate may decrease the excretion rate of Sibutramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Methylphenidate may decrease the excretion rate of Nifedipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Methylphenidate may decrease the excretion rate of Tolbutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Methylphenidate may decrease the excretion rate of Rabeprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Methylphenidate may decrease the excretion rate of Doxacurium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Methylphenidate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Methylphenidate may decrease the excretion rate of Flavoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Methylphenidate may decrease the excretion rate of Nefazodone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>Methylphenidate may decrease the excretion rate of Trimetrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Methylphenidate may decrease the excretion rate of Cilostazol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Methylphenidate may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>Methylphenidate may decrease the excretion rate of Ifosfamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>Methylphenidate may decrease the excretion rate of Naloxone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01205</drugbank-id>
      <name>Flumazenil</name>
      <description>Methylphenidate may decrease the excretion rate of Flumazenil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>Methylphenidate may decrease the excretion rate of Fomepizole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Methylphenidate may decrease the excretion rate of Estazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>Methylphenidate may decrease the excretion rate of Ketamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Methylphenidate may decrease the excretion rate of Budesonide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>Methylphenidate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>Methylphenidate may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>Methylphenidate may decrease the excretion rate of Iodixanol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Methylphenidate may decrease the excretion rate of Sitagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>Methylphenidate may decrease the excretion rate of Varenicline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Methylphenidate may decrease the excretion rate of Arformoterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>Methylphenidate may decrease the excretion rate of Colchicine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Methylphenidate may decrease the excretion rate of Tiotropium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Methylphenidate may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01427</drugbank-id>
      <name>Amrinone</name>
      <description>Methylphenidate may decrease the excretion rate of Amrinone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01428</drugbank-id>
      <name>Oxybenzone</name>
      <description>Methylphenidate may decrease the excretion rate of Oxybenzone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Methylphenidate may decrease the excretion rate of Allylestrenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01550</drugbank-id>
      <name>Fenproporex</name>
      <description>Methylphenidate may decrease the excretion rate of Fenproporex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Methylphenidate may decrease the excretion rate of Bromazepam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Methylphenidate may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Methylphenidate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>Methylphenidate may decrease the excretion rate of Ketazolam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>Methylphenidate may decrease the excretion rate of Valganciclovir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>Methylphenidate may decrease the excretion rate of Sorbitol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Methylphenidate may decrease the excretion rate of Roflumilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Methylphenidate may decrease the excretion rate of Topiroxostat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Methylphenidate may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Methylphenidate may decrease the excretion rate of Lorcaserin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>Methylphenidate may decrease the excretion rate of Pegaptanib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Methylphenidate may decrease the excretion rate of Milnacipran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Methylphenidate may decrease the excretion rate of Clevidipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Methylphenidate may decrease the excretion rate of Ezogabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>Methylphenidate may decrease the excretion rate of Migalastat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Methylphenidate may decrease the excretion rate of Brivaracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Methylphenidate may decrease the excretion rate of Apremilast which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol tetranitrate</name>
      <description>Methylphenidate may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Methylphenidate may decrease the excretion rate of Ipilimumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Methylphenidate may decrease the excretion rate of Icatibant which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Methylphenidate may decrease the excretion rate of Alogliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Methylphenidate may decrease the excretion rate of Prasugrel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>Methylphenidate may decrease the excretion rate of Doripenem which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Methylphenidate may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06230</drugbank-id>
      <name>Nalmefene</name>
      <description>Methylphenidate may decrease the excretion rate of Nalmefene which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Methylphenidate may decrease the excretion rate of Droxidopa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Methylphenidate may decrease the excretion rate of Levocetirizine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Methylphenidate may decrease the excretion rate of Saxagliptin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Methylphenidate may decrease the excretion rate of Telavancin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>Methylphenidate may decrease the excretion rate of Prucalopride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06623</drugbank-id>
      <name>Flupirtine</name>
      <description>Methylphenidate may decrease the excretion rate of Flupirtine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Methylphenidate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Methylphenidate may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Methylphenidate may decrease the excretion rate of Fesoterodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06705</drugbank-id>
      <name>Gadofosveset trisodium</name>
      <description>Methylphenidate may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Methylphenidate may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>Methylphenidate may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Methylphenidate may decrease the excretion rate of Dimercaprol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06796</drugbank-id>
      <name>Mangafodipir</name>
      <description>Methylphenidate may decrease the excretion rate of Mangafodipir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Methylphenidate may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06809</drugbank-id>
      <name>Plerixafor</name>
      <description>Methylphenidate may decrease the excretion rate of Plerixafor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>Methylphenidate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06823</drugbank-id>
      <name>Tiopronin</name>
      <description>Methylphenidate may decrease the excretion rate of Tiopronin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Methylphenidate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>Methylphenidate may decrease the excretion rate of Deferiprone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>Methylphenidate may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Methylphenidate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Methylphenidate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Methylphenidate may decrease the excretion rate of Mirabegron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>Methylphenidate may decrease the excretion rate of Peginesatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Methylphenidate may decrease the excretion rate of Aclidinium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>Methylphenidate may decrease the excretion rate of Enzalutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>Methylphenidate may decrease the excretion rate of Teduglutide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>Methylphenidate may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Methylphenidate may decrease the excretion rate of Formestane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Methylphenidate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>Methylphenidate may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>Methylphenidate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>Methylphenidate may decrease the excretion rate of Trametinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Methylphenidate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>Methylphenidate may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>Methylphenidate may decrease the excretion rate of Gemeprost which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>Methylphenidate may decrease the excretion rate of Ledipasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Methylphenidate may decrease the excretion rate of Empagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>Methylphenidate may decrease the excretion rate of Ceftolozane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>Methylphenidate may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>Methylphenidate may decrease the excretion rate of Vortioxetine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Methylphenidate may decrease the excretion rate of Tasimelteon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Methylphenidate may decrease the excretion rate of Edoxaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09081</drugbank-id>
      <name>Idebenone</name>
      <description>Methylphenidate may decrease the excretion rate of Idebenone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Methylphenidate may decrease the excretion rate of Vilanterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Methylphenidate may decrease the excretion rate of Trimebutine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Methylphenidate may decrease the excretion rate of Tixocortol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>Methylphenidate may decrease the excretion rate of Ancestim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Methylphenidate may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09106</drugbank-id>
      <name>Hydroxyethyl Starch</name>
      <description>Methylphenidate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09111</drugbank-id>
      <name>Pentastarch</name>
      <description>Methylphenidate may decrease the excretion rate of Pentastarch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>Methylphenidate may decrease the excretion rate of Stiripentol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09121</drugbank-id>
      <name>Aurothioglucose</name>
      <description>Methylphenidate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Methylphenidate may decrease the excretion rate of Dienogest which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09129</drugbank-id>
      <name>Chromic chloride</name>
      <description>Methylphenidate may decrease the excretion rate of Chromic chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09132</drugbank-id>
      <name>Gadoteric acid</name>
      <description>Methylphenidate may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09133</drugbank-id>
      <name>Iothalamic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>Methylphenidate may decrease the excretion rate of Ioversol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>Methylphenidate may decrease the excretion rate of Ioxilan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09136</drugbank-id>
      <name>Isosulfan blue</name>
      <description>Methylphenidate may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>Methylphenidate may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Methylphenidate may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09148</drugbank-id>
      <name>Florbetaben (18F)</name>
      <description>Methylphenidate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09149</drugbank-id>
      <name>Florbetapir (18F)</name>
      <description>Methylphenidate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>Methylphenidate may decrease the excretion rate of Iopromide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09163</drugbank-id>
      <name>Technetium Tc-99m exametazime</name>
      <description>Methylphenidate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09164</drugbank-id>
      <name>Technetium Tc-99m disofenin</name>
      <description>Methylphenidate may decrease the excretion rate of Technetium Tc-99m disofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09165</drugbank-id>
      <name>Technetium Tc-99m pyrophosphate</name>
      <description>Methylphenidate may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Methylphenidate may decrease the excretion rate of Viloxazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Methylphenidate may decrease the excretion rate of Etoperidone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>Methylphenidate may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Methylphenidate may decrease the excretion rate of Arotinolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Methylphenidate may decrease the excretion rate of Moxisylyte which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09209</drugbank-id>
      <name>Pholcodine</name>
      <description>Methylphenidate may decrease the excretion rate of Pholcodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09210</drugbank-id>
      <name>Piracetam</name>
      <description>Methylphenidate may decrease the excretion rate of Piracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>Methylphenidate may decrease the excretion rate of Bisoxatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Methylphenidate may decrease the excretion rate of Dextran which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>Methylphenidate may decrease the excretion rate of Tegafur which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>Methylphenidate may decrease the excretion rate of Gimeracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Methylphenidate may decrease the excretion rate of Imidafenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Methylphenidate may decrease the excretion rate of Idarucizumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Methylphenidate may decrease the excretion rate of Lixisenatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>Methylphenidate may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>Methylphenidate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Methylphenidate may decrease the excretion rate of Choline C 11 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Methylphenidate may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Methylphenidate may decrease the excretion rate of Sacubitril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09301</drugbank-id>
      <name>Chondroitin sulfate</name>
      <description>Methylphenidate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Methylphenidate may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Methylphenidate may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>Methylphenidate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09324</drugbank-id>
      <name>Sulbactam</name>
      <description>Methylphenidate may decrease the excretion rate of Sulbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09325</drugbank-id>
      <name>Sodium fluoride</name>
      <description>Methylphenidate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Methylphenidate may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Methylphenidate may decrease the excretion rate of Mersalyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09344</drugbank-id>
      <name>Invert sugar</name>
      <description>Methylphenidate may decrease the excretion rate of Invert sugar which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09357</drugbank-id>
      <name>Dexpanthenol</name>
      <description>Methylphenidate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09394</drugbank-id>
      <name>Phosphoric acid</name>
      <description>Methylphenidate may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09395</drugbank-id>
      <name>Sodium acetate</name>
      <description>Methylphenidate may decrease the excretion rate of Sodium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Methylphenidate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Methylphenidate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>Methylphenidate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Methylphenidate may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>Methylphenidate may decrease the excretion rate of Acrivastine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09496</drugbank-id>
      <name>Octinoxate</name>
      <description>Methylphenidate may decrease the excretion rate of Octinoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09502</drugbank-id>
      <name>Fludeoxyglucose (18F)</name>
      <description>Methylphenidate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09546</drugbank-id>
      <name>Iobenguane sulfate I-123</name>
      <description>Methylphenidate may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>Methylphenidate may decrease the excretion rate of Ixazomib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>Methylphenidate may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>Methylphenidate may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Methylphenidate may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11102</drugbank-id>
      <name>N-acetyltyrosine</name>
      <description>Methylphenidate may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11114</drugbank-id>
      <name>Eucalyptus oil</name>
      <description>Methylphenidate may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11127</drugbank-id>
      <name>Selenious acid</name>
      <description>Methylphenidate may decrease the excretion rate of Selenious acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>Methylphenidate may decrease the excretion rate of Opium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11135</drugbank-id>
      <name>Selenium</name>
      <description>Methylphenidate may decrease the excretion rate of Selenium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11136</drugbank-id>
      <name>Chromium</name>
      <description>Methylphenidate may decrease the excretion rate of Chromium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11145</drugbank-id>
      <name>Oxyquinoline</name>
      <description>Methylphenidate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Methylphenidate may decrease the excretion rate of Pyrantel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11164</drugbank-id>
      <name>Bicisate</name>
      <description>Methylphenidate may decrease the excretion rate of Bicisate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11251</drugbank-id>
      <name>Tocopherol</name>
      <description>Methylphenidate may decrease the excretion rate of Tocopherol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>Methylphenidate may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11328</drugbank-id>
      <name>Tetradecyl hydrogen sulfate (ester)</name>
      <description>Methylphenidate may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11338</drugbank-id>
      <name>Clove oil</name>
      <description>Methylphenidate may decrease the excretion rate of Clove oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Methylphenidate may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11364</drugbank-id>
      <name>Pidotimod</name>
      <description>Methylphenidate may decrease the excretion rate of Pidotimod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>Methylphenidate may decrease the excretion rate of Lesinurad which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11577</drugbank-id>
      <name>Indigotindisulfonic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>Methylphenidate may decrease the excretion rate of Etafedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Methylphenidate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>Methylphenidate may decrease the excretion rate of Pitolisant which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11691</drugbank-id>
      <name>Naldemedine</name>
      <description>Methylphenidate may decrease the excretion rate of Naldemedine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Methylphenidate may decrease the excretion rate of Tropisetron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>Methylphenidate may decrease the excretion rate of Baricitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>Methylphenidate may decrease the excretion rate of Apalutamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>Methylphenidate may decrease the excretion rate of Valbenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Methylphenidate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11989</drugbank-id>
      <name>Benznidazole</name>
      <description>Methylphenidate may decrease the excretion rate of Benznidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12007</drugbank-id>
      <name>Isoflavone</name>
      <description>Methylphenidate may decrease the excretion rate of Isoflavone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12107</drugbank-id>
      <name>Vaborbactam</name>
      <description>Methylphenidate may decrease the excretion rate of Vaborbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>Methylphenidate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Methylphenidate may decrease the excretion rate of Propiverine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>Methylphenidate may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>Methylphenidate may decrease the excretion rate of Nedaplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13156</drugbank-id>
      <name>Inosine pranobex</name>
      <description>Methylphenidate may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13178</drugbank-id>
      <name>Inositol</name>
      <description>Methylphenidate may decrease the excretion rate of Inositol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13185</drugbank-id>
      <name>Oxabolone cipionate</name>
      <description>Methylphenidate may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13191</drugbank-id>
      <name>Phosphocreatine</name>
      <description>Methylphenidate may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13269</drugbank-id>
      <name>Dichlorobenzyl alcohol</name>
      <description>Methylphenidate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>Methylphenidate may decrease the excretion rate of Ipecac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Methylphenidate may decrease the excretion rate of Almasilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>Methylphenidate may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Methylphenidate may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Methylphenidate may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Methylphenidate may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Methylphenidate may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Methylphenidate may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Methylphenidate may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>Methylphenidate may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Methylphenidate may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>Methylphenidate may decrease the excretion rate of Patent Blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>Methylphenidate may decrease the excretion rate of Choline salicylate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14007</drugbank-id>
      <name>Pentetic acid</name>
      <description>Methylphenidate may decrease the excretion rate of Pentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>Methylphenidate may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14186</drugbank-id>
      <name>Cinnamyl alcohol</name>
      <description>Methylphenidate may decrease the excretion rate of Cinnamyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Methylphenidate may decrease the excretion rate of Potassium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>Methylphenidate may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14526</drugbank-id>
      <name>Chromic citrate</name>
      <description>Methylphenidate may decrease the excretion rate of Chromic citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14527</drugbank-id>
      <name>Chromic nitrate</name>
      <description>Methylphenidate may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14528</drugbank-id>
      <name>Chromium gluconate</name>
      <description>Methylphenidate may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14529</drugbank-id>
      <name>Chromium nicotinate</name>
      <description>Methylphenidate may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14530</drugbank-id>
      <name>Chromous sulfate</name>
      <description>Methylphenidate may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06815</drugbank-id>
      <name>Pyrithione</name>
      <description>Methylphenidate may decrease the excretion rate of Pyrithione which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11121</drugbank-id>
      <name>Chloroxylenol</name>
      <description>Methylphenidate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>Methylphenidate may decrease the excretion rate of Resorcinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15593</drugbank-id>
      <name>Golodirsen</name>
      <description>Methylphenidate may decrease the excretion rate of Golodirsen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>Methylphenidate may decrease the excretion rate of Capreomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Methylphenidate may decrease the excretion rate of Codeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Methylphenidate may decrease the excretion rate of Amitriptyline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Methylphenidate may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>Methylphenidate may decrease the excretion rate of Meperidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Methylphenidate may decrease the excretion rate of Imipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>Methylphenidate may decrease the excretion rate of Vancomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>Methylphenidate may decrease the excretion rate of Cisplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>Methylphenidate may decrease the excretion rate of Carbamazepine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>Methylphenidate may decrease the excretion rate of Pemetrexed which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Methylphenidate may decrease the excretion rate of Fentanyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>Methylphenidate may decrease the excretion rate of Emtricitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Methylphenidate may decrease the excretion rate of Quinidine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Methylphenidate may decrease the excretion rate of Isotretinoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Methylphenidate may decrease the excretion rate of Procainamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Methylphenidate may decrease the excretion rate of Desipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Methylphenidate may decrease the excretion rate of Clomipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Methylphenidate may decrease the excretion rate of Lithium cation which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Methylphenidate may decrease the excretion rate of Dimetacrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>Methylphenidate may decrease the excretion rate of Plazomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>Methylphenidate may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>Methylphenidate may decrease the excretion rate of Lithium citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14508</drugbank-id>
      <name>Lithium succinate</name>
      <description>Methylphenidate may decrease the excretion rate of Lithium succinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>Methylphenidate may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>Methylphenidate may increase the excretion rate of Ibopamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Ethoxzolamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Spironolactone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Amiloride may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Methazolamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Acetazolamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>Conivaptan may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Diclofenamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Quinethazone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>Theobromine may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Piretanide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>Ularitide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>Tolvaptan may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Dapagliflozin may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>Indisulam may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Azosemide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>Canrenoic acid may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Potassium citrate may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>Isosorbide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Ertugliflozin may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>Canrenone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>Rolofylline may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>Spiradoline may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Meticrane may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Mefruside may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Clorexolone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Clofenamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Fenquizone may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Clopamide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Epitizide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>Bromotheophylline may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The therapeutic efficacy of Trimethadione can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The therapeutic efficacy of Methohexital can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The therapeutic efficacy of Paramethadione can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The therapeutic efficacy of Tizanidine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The therapeutic efficacy of Riluzole can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The therapeutic efficacy of Ethotoin can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The therapeutic efficacy of Phensuximide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The therapeutic efficacy of Tiagabine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The therapeutic efficacy of Felbamate can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The therapeutic efficacy of Phenacemide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The therapeutic efficacy of Thiamylal can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The therapeutic efficacy of Delorazepam can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The therapeutic efficacy of Valpromide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The therapeutic efficacy of Flunarizine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The therapeutic efficacy of Methsuximide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The therapeutic efficacy of Rufinamide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The therapeutic efficacy of Lacosamide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The therapeutic efficacy of Remacemide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The therapeutic efficacy of Deramciclane can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The therapeutic efficacy of Sulthiame can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The therapeutic efficacy of Perampanel can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The therapeutic efficacy of Beclamide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The therapeutic efficacy of Doramectin can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The therapeutic efficacy of Tiletamine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The therapeutic efficacy of Brexanolone can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The therapeutic efficacy of Etiracetam can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The therapeutic efficacy of Carisbamate can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The therapeutic efficacy of Pheneturide can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The therapeutic efficacy of Medazepam can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The therapeutic efficacy of Phenibut can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The therapeutic efficacy of Ethadione can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The therapeutic efficacy of Gabapentin can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The therapeutic efficacy of Cenobamate can be decreased when used in combination with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of adverse effects can be increased when Disulfiram is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of seizure can be increased when Methylphenidate is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The risk or severity of hypertension can be increased when Esketamine is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The risk or severity of hypertension can be increased when Solriamfetol is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Testosterone undecanoate may increase the hypertensive activities of Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>The risk or severity of seizure can be increased when Methylphenidate is combined with Dalfampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The risk or severity of seizure can be increased when Methylphenidate is combined with Bupropion.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.47</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.82e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>methyl 2-phenyl-2-(piperidin-2-yl)acetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>methylphenidate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>233.3062</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>233.141578857</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC(=O)C(C1CCCCN1)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H19NO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>DUGOZIWVEXMGBE-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>38.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>66.73</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>26.21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.09</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1255mg/L</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6186</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>84276</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4158</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505929</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07196</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04999</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4015</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50062912</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450464</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000024</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Methylphenidate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL796</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/methphen.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rit1383.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/methylphenidate.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00422</drugbank-id>
        <name>Methylphenidate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02308</drugbank-id>
        <name>α-phenyl-2-piperidine acetic acid (ritalinic acid)</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0004740</drugbank-id>
          <name>Carboxylesterase</name>
          <uniprot-id>Q6LAP9</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000647</id>
      <name>Sodium-dependent dopamine transporter</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4829</ref-id>
            <pubmed-id>10025684</pubmed-id>
            <citation>Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66.</citation>
          </article>
          <article>
            <ref-id>A4830</ref-id>
            <pubmed-id>10037500</pubmed-id>
            <citation>Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74.</citation>
          </article>
          <article>
            <ref-id>A4831</ref-id>
            <pubmed-id>10199939</pubmed-id>
            <citation>Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7.</citation>
          </article>
          <article>
            <ref-id>A4832</ref-id>
            <pubmed-id>10403500</pubmed-id>
            <citation>Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12.</citation>
          </article>
          <article>
            <ref-id>A4833</ref-id>
            <pubmed-id>10414438</pubmed-id>
            <citation>Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A4334</ref-id>
            <pubmed-id>9537821</pubmed-id>
            <citation>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</citation>
          </article>
          <article>
            <ref-id>A4834</ref-id>
            <pubmed-id>15303308</pubmed-id>
            <citation>Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 2004;11(1-2):97-114.</citation>
          </article>
          <article>
            <ref-id>A4835</ref-id>
            <pubmed-id>18698001</pubmed-id>
            <citation>Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub  2008 Aug 12.</citation>
          </article>
          <article>
            <ref-id>A632</ref-id>
            <pubmed-id>17201613</pubmed-id>
            <citation>Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98.</citation>
          </article>
          <article>
            <ref-id>A177541</ref-id>
            <pubmed-id>16806100</pubmed-id>
            <citation>Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC: Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006 Nov 15;60(10):1111-20. doi: 10.1016/j.biopsych.2006.04.022. Epub 2006 Jun 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q01959" source="Swiss-Prot">
        <name>Sodium-dependent dopamine transporter</name>
        <general-function>Monoamine transmembrane transporter activity</general-function>
        <specific-function>Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.</specific-function>
        <gene-name>SLC6A3</gene-name>
        <locus>5p15.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>69-89
96-116
140-160
238-256
265-282
318-335
347-368
401-420
447-465
481-501
522-541
560-578</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.92</theoretical-pi>
        <molecular-weight>68494.255</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11049</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC6A3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M96670</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>553260</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>927</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q01959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SC6A3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>DA transporter</synonym>
          <synonym>DAT1</synonym>
          <synonym>Solute carrier family 6 member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010450|Sodium-dependent dopamine transporter
MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDR
ETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELAL
GQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHC
NNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQL
TACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSV
DFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSS
GFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGI
DSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAA
GTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSI
VTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKD
RELVDRGEVRQFTLRHWLKV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010451|Sodium-dependent dopamine transporter (SLC6A3)
ATGAGTAAGAGCAAATGCTCCGTGGGACTCATGTCTTCCGTGGTGGCCCCGGCTAAGGAG
CCCAATGCCGTGGGCCCGAAGGAGGTGGAGCTCATCCTTGTCAAGGAGCAGAACGGAGTG
CAGCTCACCAGCTCCACCCTCACCAACCCGCGGCAGAGCCCCGTGGAGGCCCAGGATCGG
GAGACCTGGGGCAAGAAGATCGACTTTCTCCTGTCCGTCATTGGCTTTGCTGTGGACCTG
GCCAACGTCTGGCGGTTCCCCTACCTGTGCTACAAAAATGGTGGCGGTGCCTTCCTGGTC
CCCTACCTGCTCTTCATGGTCATTGCTGGGATGCCACTTTTCTACATGGAGCTGGCCCTC
GGCCAGTTCAACAGGGAAGGGGCCGCTGGTGTCTGGAAGATCTGCCCCATACTGAAAGGT
GTGGGCTTCACGGTCATCCTCATCTCACTGTATGTCGGCTTCTTCTACAACGTCATCATC
GCCTGGGCGCTGCACTATCTCTTCTCCTCCTTCACCACGGAGCTCCCCTGGATCCACTGC
AACAACTCCTGGAACAGCCCCAACTGCTCGGATGCCCATCCTGGTGACTCCAGTGGAGAC
AGCTCGGGCCTCAACGACACTTTTGGGACCACACCTGCTGCCGAGTACTTTGAACGTGGC
GTGCTGCACCTCCACCAGAGCCATGGCATCGACGACCTGGGGCCTCCGCGGTGGCAGCTC
ACAGCCTGCCTGGTGCTGGTCATCGTGCTGCTCTACTTCAGCCTCTGGAAGGGCGTGAAG
ACCTCAGGGAAGGTGGTATGGATCACAGCCACCATGCCATACGTGGTCCTCACTGCCCTG
CTCCTGCGTGGGGTCACCCTCCCTGGAGCCATAGACGGCATCAGAGCATACCTGAGCGTT
GACTTCTACCGGCTCTGCGAGGCGTCTGTTTGGATTGACGCGGCCACCCAGGTGTGCTTC
TCCCTGGGCGTGGGGTTCGGGGTGCTGATCGCCTTCTCCAGCTACAACAAGTTCACCAAC
AACTGCTACAGGGACGCGATTGTCACCACCTCCATCAACTCCCTGACGAGCTTCTCCTCC
GGCTTCGTCGTCTTCTCCTTCCTGGGGTACATGGCACAGAAGCACAGTGTGCCCATCGGG
GACGTGGCCAAGGACGGGCCAGGGCTGATCTTCATCATCTACCCGGAAGCCATCGCCACG
CTCCCTCTGTCCTCAGCCTGGGCCGTGGTCTTCTTCATCATGCTGCTCACCCTGGGTATC
GACAGCGCCATGGGTGGTATGGAGTCAGTGATCACCGGGCTCATCGATGAGTTCCAGCTG
CTGCACAGACACCGTGAGCTCTTCACGCTCTTCATCGTCCTGGCGACCTTCCTCCTGTCC
CTGTTCTGCGTCACCAACGGTGGCATCTACGTCTTCACGCTCCTGGACCATTTTGCAGCC
GGCACGTCCATCCTCTTTGGAGTGCTCATCGAAGCCATCGGAGTGGCCTGGTTCTATGGT
GTTGGGCAGTTCAGCGACGACATCCAGCAGATGACCGGGCAGCGGCCCAGCCTGTACTGG
CGGCTGTGCTGGAAGCTGGTCAGCCCCTGCTTTCTCCTGTTCGTGGTCGTGGTCAGCATT
GTGACCTTCAGACCCCCCCACTACGGAGCCTACATCTTCCCCGACTGGGCCAACGCGCTG
GGCTGGGTCATCGCCACATCCTCCATGGCCATGGTGCCCATCTATGCGGCCTACAAGTTC
TGCAGCCTGCCTGGGTCCTTTCGAGAGAAACTGGCCTACGCCATTGCACCCGAGAAGGAC
CGTGAGCTGGTGGACAGAGGGGAGGTGCGCCAGTTCACGCTCCGCCACTGGCTCAAGGTG
TAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00209</identifier>
            <name>SNF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>flotillin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monoamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenohypophysis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of smell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000486</id>
      <name>Sodium-dependent noradrenaline transporter</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10517</ref-id>
            <pubmed-id>15322419</pubmed-id>
            <citation>Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8.</citation>
          </article>
          <article>
            <ref-id>A10518</ref-id>
            <pubmed-id>17218796</pubmed-id>
            <citation>Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51.</citation>
          </article>
          <article>
            <ref-id>A10519</ref-id>
            <pubmed-id>16246598</pubmed-id>
            <citation>Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat. Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24.</citation>
          </article>
          <article>
            <ref-id>A10520</ref-id>
            <pubmed-id>17611273</pubmed-id>
            <citation>Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207.</citation>
          </article>
          <article>
            <ref-id>A10521</ref-id>
            <pubmed-id>11160413</pubmed-id>
            <citation>Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9.</citation>
          </article>
          <article>
            <ref-id>A4334</ref-id>
            <pubmed-id>9537821</pubmed-id>
            <citation>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</citation>
          </article>
          <article>
            <ref-id>A4835</ref-id>
            <pubmed-id>18698001</pubmed-id>
            <citation>Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub  2008 Aug 12.</citation>
          </article>
          <article>
            <ref-id>A632</ref-id>
            <pubmed-id>17201613</pubmed-id>
            <citation>Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98.</citation>
          </article>
          <article>
            <ref-id>A177541</ref-id>
            <pubmed-id>16806100</pubmed-id>
            <citation>Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC: Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006 Nov 15;60(10):1111-20. doi: 10.1016/j.biopsych.2006.04.022. Epub 2006 Jun 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P23975" source="Swiss-Prot">
        <name>Sodium-dependent noradrenaline transporter</name>
        <general-function>Norepinephrine:sodium symporter activity</general-function>
        <specific-function>Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.</specific-function>
        <gene-name>SLC6A2</gene-name>
        <locus>16q12.2</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>65-85
93-112
136-156
235-253
262-279
315-332
344-365
398-417
444-462
478-498
519-538
557-575</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.53</theoretical-pi>
        <molecular-weight>69331.42</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11048</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC6A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M65105</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189258</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>926</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SC6A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NAT1</synonym>
          <synonym>NET</synonym>
          <synonym>NET1</synonym>
          <synonym>Norepinephrine transporter</synonym>
          <synonym>SLC6A5</synonym>
          <synonym>Solute carrier family 6 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000970|Sodium-dependent noradrenaline transporter
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
VAQRDIRQFQLQHWLAI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010343|Sodium-dependent noradrenaline transporter (SLC6A2)
ATGCTTCTGGCGCGGATGAACCCGCAGGTGCAGCCCGAGAACAACGGGGCGGACACGGGT
CCAGAGCAGCCCCTTCGGGCGCGCAAAACTGCGGAGCTGCTGGTGGTGAAGGAGCGCAAC
GGCGTCCAGTGCCTGCTGGCGCCCCGCGACGGCGACGCGCAGCCCCGGGAGACCTGGGGC
AAGAAGATCGACTTCCTGCTGTCCGTAGTCGGCTTCGCAGTGGACCTGGCCAACGTGTGG
CGCTTCCCCTACCTCTGCTACAAGAACGGCGGCGGTGCCTTCTTGATCCCGTACACACTG
TTCCTTATCATCGCGGGGATGCCCCTGTTCTACATGGAGCTGGCTCTGGGACAGTACAAC
CGGGAGGGGGCTGCCACCGTTTGGAAAATCTGCCCATTCTTCAAAGGCGTTGGCTATGCT
GTCATCCTGATCGCCCTGTACGTTGGCTTCTACTACAACGTCATCATCGCCTGGTCACTC
TACTACCTCTTCTCCTCCTTCACCCTCAACCTGCCCTGGACCGACTGTGGCCACACCTGG
AACAGCCCCAACTGTACCGACCCCAAGCTCCTCAATGGCTCCGTGCTTGGCAACCACACC
AAGTACTCCAAGTACAAGTTCACGCCGGCAGCCGAGTTTTATGAGCGTGGTGTCCTGCAC
CTTCACGAGAGCAGCGGGATTCATGACATCGGCCTGCCCCAGTGGCAGCTCTTGCTCTGT
CTGATGGTCGTCGTCATCGTCTTGTATTTTAGCCTCTGGAAAGGGGTGAAGACATCAGGA
AAGGTGGTGTGGATCACAGCCACGCTGCCTTACTTCGTGCTGTTCGTGCTCCTGGTCCAT
GGCGTCACGCTGCCCGGAGCCTCCAATGGCATCAATGCCTACCTGCACATCGACTTCTAC
CGCTTGAAAGAGGCCACGGTATGGATTGATGCCGCAACTCAGATATTTTTTTCCTTGGGG
GCTGGATTTGGAGTATTGATTGCATTTGCCAGTTACAACAAATTTGACAACAACTGTTAC
AGGGATGCCCTGCTGACCAGCAGCATCAACTGTATCACCAGCTTCGTCTCTGGGTTCGCC
ATCTTCTCCATCCTTGGTTACATGGCCCATGAACACAAGGTCAACATTGAGGATGTGGCC
ACAGAAGGAGCTGGCCTAGTGTTCATCCTGTATCCAGAGGCCATTTCTACCCTGTCTGGA
TCTACATTCTGGGCTGTTGTGTTTTTCGTCATGCTCCTGGCGCTGGGCCTTGACAGCTCA
ATGGGAGGCATGGAGGCTGTCATCACGGGCCTGGCAGATGACTTCCAGGTCCTGAAGCGA
CACCGGAAACTCTTCACATTTGGCGTCACCTTCAGCACTTTCCTTCTCGCCCTGTTCTGC
ATAACCAAGGGTGGAATTTACGTCTTGACCCTCCTGGACACCTTTGCTGCGGGCACCTCC
ATCCTTTTTGCTGTCCTCATGGAAGCCATCGGAGTTTCCTGGTTTTATGGAGTGGACAGG
TTCAGCAACGACATCCAGCAGATGATGGGGTTCAGGCCGGGTCTATACTGGAGACTGTGC
TGGAAGTTCGTCAGTCCTGCCTTCCTCCTGTTCGTGGTTGTGGTCAGCATCATCAACTTC
AAGCCACTCACCTACGACGACTACATCTTCCCGCCCTGGGCCAACTGGGTGGGGTGGGGC
ATCGCCCTGTCCTCCATGGTCCTGGTGCCCATCTACGTCATCTATAAGTTCCTCAGCACG
CAGGGCTCTCTTTGGGAGAGACTGGCCTATGGCATCACGCCAGAGAACGAGCACCACCTG
GTGGCTCAGAGGGACATCAGACAGTTCCAGTTGCAACACTGGCTGGCCATCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00209</identifier>
            <name>SNF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monoamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000291</id>
      <name>5-hydroxytryptamine receptor 1A</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A177562</ref-id>
            <pubmed-id>19322953</pubmed-id>
            <citation>Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ: The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Pharmazie. 2009 Feb;64(2):123-5.</citation>
          </article>
          <article>
            <ref-id>A632</ref-id>
            <pubmed-id>17201613</pubmed-id>
            <citation>Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08908" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 1A</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.</specific-function>
        <gene-name>HTR1A</gene-name>
        <locus>5q11.2-q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>37-62
74-98
111-132
153-178
192-217
346-367
379-403</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>46106.335</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5286</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M28269</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08908</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1A</synonym>
          <synonym>ADRB2RL1</synonym>
          <synonym>ADRBRL1</synonym>
          <synonym>G-21</synonym>
          <synonym>Serotonin receptor 1A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018934|5-hydroxytryptamine receptor 1A
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC
TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN
SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP
FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC
RQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A)
ATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG
ACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT
CTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC
ATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC
ACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC
AAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC
ACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC
CCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT
TGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC
CGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC
TTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA
GCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC
CGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC
AGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG
GTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC
TCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT
TTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG
AGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC
TTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG
TTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC
GCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC
CGCCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exploration behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of serotonin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0004740</id>
      <name>Carboxylesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176038</ref-id>
            <pubmed-id>15082749</pubmed-id>
            <citation>Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76. doi: 10.1124/jpet.104.067116. Epub 2004 Apr 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q6LAP9" source="TrEMBL">
        <name>Carboxylesterase</name>
        <general-function>Carboxylic ester hydrolase activity</general-function>
        <specific-function/>
        <gene-name>CES1A1a</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>1908.25</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q6LAP9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q6LAP9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Carboxylesterase 1A1</synonym>
          <synonym>CES1A1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019626|Carboxylesterase
MWLRAFILATLSASAAW</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams/>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>carboxylic ester hydrolase activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>